0001360214 2022-01-01 2022-09-30 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2022-01-01 2022-09-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2022-01-01 2022-09-30 0001360214 2022-11-11 0001360214 2022-09-30 0001360214 2021-12-31 0001360214 2022-07-01 2022-09-30 0001360214 2021-07-01 2021-09-30 0001360214 2021-01-01 2021-09-30 0001360214 HROW:ProductSalesNetMember 2022-07-01 2022-09-30 0001360214 HROW:ProductSalesNetMember 2021-07-01 2021-09-30 0001360214 HROW:ProductSalesNetMember 2022-01-01 2022-09-30 0001360214 HROW:ProductSalesNetMember 2021-01-01 2021-09-30 0001360214 HROW:OtherRevenuesMember 2022-07-01 2022-09-30 0001360214 HROW:OtherRevenuesMember 2021-07-01 2021-09-30 0001360214 HROW:OtherRevenuesMember 2022-01-01 2022-09-30 0001360214 HROW:OtherRevenuesMember 2021-01-01 2021-09-30 0001360214 us-gaap:PreferredStockMember 2020-12-31 0001360214 us-gaap:CommonStockMember 2020-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001360214 us-gaap:RetainedEarningsMember 2020-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-12-31 0001360214 2020-12-31 0001360214 us-gaap:PreferredStockMember 2021-12-31 0001360214 us-gaap:CommonStockMember 2021-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001360214 us-gaap:RetainedEarningsMember 2021-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2021-12-31 0001360214 us-gaap:PreferredStockMember 2021-06-30 0001360214 us-gaap:CommonStockMember 2021-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001360214 us-gaap:RetainedEarningsMember 2021-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-06-30 0001360214 2021-06-30 0001360214 us-gaap:PreferredStockMember 2022-06-30 0001360214 us-gaap:CommonStockMember 2022-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001360214 us-gaap:RetainedEarningsMember 2022-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2022-06-30 0001360214 2022-06-30 0001360214 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001360214 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001360214 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-01-01 2021-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0001360214 us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001360214 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001360214 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-01-01 2022-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001360214 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001360214 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001360214 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-07-01 2021-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001360214 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001360214 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001360214 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-07-01 2022-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001360214 us-gaap:PreferredStockMember 2021-09-30 0001360214 us-gaap:CommonStockMember 2021-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001360214 us-gaap:RetainedEarningsMember 2021-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-09-30 0001360214 2021-09-30 0001360214 us-gaap:PreferredStockMember 2022-09-30 0001360214 us-gaap:CommonStockMember 2022-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001360214 us-gaap:RetainedEarningsMember 2022-09-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2022-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2022-09-30 0001360214 HROW:StockOptionsUnvestedRSUsAndWarrantsMember 2022-01-01 2022-09-30 0001360214 HROW:StockOptionsUnvestedRSUsAndWarrantsMember 2021-01-01 2021-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-09-30 0001360214 srt:MaximumMember HROW:EtonPharmaceuticalsIncMember 2022-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-07-01 2022-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-07-01 2021-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-01-01 2021-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001360214 HROW:SurfaceOphthalmicsIncMember 2022-09-30 0001360214 HROW:SurfaceOphthalmicsIncMember 2021-01-01 2021-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001360214 HROW:SurfaceOphthalmicsIncMember 2022-01-01 2022-09-30 0001360214 us-gaap:CommonStockMember HROW:MeltPharmaceuticalsIncMember 2022-09-30 0001360214 HROW:LoanMember HROW:MeltPharmaceuticalsIncMember 2022-09-30 0001360214 HROW:LoanMember HROW:MeltPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-09-30 0001360214 us-gaap:CommonStockMember HROW:SurfaceOphthalmicsIncMember 2022-09-30 0001360214 HROW:CommissionsMember 2022-07-01 2022-09-30 0001360214 HROW:CommissionsMember 2021-07-01 2021-09-30 0001360214 HROW:CommissionsMember 2022-01-01 2022-09-30 0001360214 HROW:CommissionsMember 2021-01-01 2021-09-30 0001360214 HROW:TransferOfProfitMember 2022-07-01 2022-09-30 0001360214 HROW:TransferOfProfitMember 2021-07-01 2021-09-30 0001360214 HROW:TransferOfProfitMember 2022-01-01 2022-09-30 0001360214 HROW:TransferOfProfitMember 2021-01-01 2021-09-30 0001360214 us-gaap:LicenseMember 2022-07-01 2022-09-30 0001360214 us-gaap:LicenseMember 2021-07-01 2021-09-30 0001360214 us-gaap:LicenseMember 2022-01-01 2022-09-30 0001360214 us-gaap:LicenseMember 2021-01-01 2021-09-30 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:MeltPharmaceuticalsIncMember 2022-07-01 2022-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-12-31 0001360214 HROW:MeltLoanAgreementMember 2021-09-01 0001360214 HROW:ThirdPartyInvestorMember HROW:MeltLoanAgreementMember 2021-09-30 0001360214 HROW:MeltLoanAgreementMember 2021-08-29 2021-09-01 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2022-09-30 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2021-12-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-09-30 0001360214 HROW:SurfaceOphthalmicsIncMember 2022-09-30 0001360214 HROW:SurfaceOphthalmicsIncMember 2021-12-31 0001360214 HROW:SurfaceOphthalmicsIncMember 2021-01-01 2021-09-30 0001360214 HROW:CapitalizedInternalUseSoftwareMember 2022-09-30 0001360214 HROW:CapitalizedInternalUseSoftwareMember 2021-12-31 0001360214 HROW:ThirdPartySoftwareLicenseMember 2022-09-30 0001360214 HROW:ThirdPartySoftwareLicenseMember 2021-12-31 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2022-07-01 2022-09-30 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2022-01-01 2022-09-30 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2021-07-01 2021-09-30 0001360214 HROW:CapitalizedSoftwareDevelopmentCostsMember 2021-01-01 2021-09-30 0001360214 srt:MinimumMember us-gaap:PatentsMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember us-gaap:PatentsMember 2022-01-01 2022-09-30 0001360214 us-gaap:PatentsMember 2022-09-30 0001360214 HROW:LicensesMember 2022-01-01 2022-09-30 0001360214 HROW:LicensesMember 2022-09-30 0001360214 us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001360214 us-gaap:TrademarksMember 2022-09-30 0001360214 HROW:NewDrugApplicationsMember 2022-01-01 2022-06-30 0001360214 HROW:NewDrugApplicationsMember 2022-09-30 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2022-09-30 0001360214 us-gaap:TradeNamesMember 2022-01-01 2022-09-30 0001360214 us-gaap:TradeNamesMember 2022-09-30 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2022-01-01 2022-09-30 0001360214 HROW:NonCompetitionClauseMember 2022-09-30 0001360214 HROW:StatePharmacyLicensesMember 2022-01-01 2022-09-30 0001360214 HROW:StatePharmacyLicensesMember 2022-09-30 0001360214 us-gaap:PatentsMember 2022-07-01 2022-09-30 0001360214 us-gaap:PatentsMember 2021-07-01 2021-09-30 0001360214 us-gaap:PatentsMember 2022-01-01 2022-09-30 0001360214 us-gaap:PatentsMember 2021-01-01 2021-09-30 0001360214 HROW:LicensesMember 2022-07-01 2022-09-30 0001360214 HROW:LicensesMember 2021-07-01 2021-09-30 0001360214 HROW:LicensesMember 2021-01-01 2021-09-30 0001360214 HROW:NewDrugApplicationsMember 2022-07-01 2022-09-30 0001360214 HROW:NewDrugApplicationsMember 2021-07-01 2021-09-30 0001360214 HROW:NewDrugApplicationsMember 2022-01-01 2022-09-30 0001360214 HROW:NewDrugApplicationsMember 2021-01-01 2021-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2022-07-01 2022-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2021-07-01 2021-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-09-30 0001360214 HROW:FinancingAgreementMember 2022-01-01 2022-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-05-01 2021-05-31 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-06-01 2021-06-30 0001360214 us-gaap:InvestorMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-06-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-06-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-04-01 2021-04-30 0001360214 srt:ScenarioForecastMember HROW:SeniorNotesDueTwoThousandTwentySixMember 2026-01-30 2026-01-31 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2022-07-01 2022-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2022-01-01 2022-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-07-01 2021-09-30 0001360214 HROW:SeniorNotesDueTwoThousandTwentySixMember 2021-01-01 2021-09-30 0001360214 srt:MinimumMember HROW:OfficeAndLaboratorySpaceMember 2022-09-30 0001360214 srt:MaximumMember HROW:OfficeAndLaboratorySpaceMember 2022-09-30 0001360214 HROW:CarlsbadMember 2022-09-30 0001360214 HROW:CarlsbadMember 2022-01-01 2022-09-30 0001360214 HROW:LedgewoodMember 2022-09-30 0001360214 HROW:LedgewoodMember 2022-01-01 2022-09-30 0001360214 HROW:LedgewoodMember HROW:LeaseAmendmentMember 2022-01-01 2022-09-30 0001360214 HROW:NashvilleMember 2022-09-30 0001360214 HROW:NashvilleMember 2022-01-01 2022-09-30 0001360214 HROW:Nashville1Member 2022-09-30 0001360214 HROW:Nashville1Member 2022-01-01 2022-09-30 0001360214 HROW:MarkLBaumMember 2022-01-01 2022-09-30 0001360214 HROW:ConsultantsMember us-gaap:OptionMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 us-gaap:OptionMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 srt:MinimumMember us-gaap:OptionMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember us-gaap:OptionMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 HROW:AndrewRBollMember 2022-01-01 2022-09-30 0001360214 HROW:AndrewRBollMember 2022-02-01 2022-02-28 0001360214 HROW:JohnPSaharekMember 2022-01-01 2022-09-30 0001360214 HROW:JohnPSaharekMember 2022-02-01 2022-02-28 0001360214 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember HROW:FebruaryTwoThousandNineteenMember 2022-01-01 2022-09-30 0001360214 us-gaap:CommonStockMember 2022-02-01 2022-02-28 0001360214 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember HROW:MayTwoThousandNineteenMember 2022-01-01 2022-09-30 0001360214 us-gaap:CommonStockMember 2022-05-01 2022-05-31 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2022-09-30 0001360214 HROW:StockOptionPlanMember 2022-09-30 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2022-01-01 2022-09-30 0001360214 HROW:EmployeesAndDirectorsMember 2022-01-01 2022-09-30 0001360214 HROW:StockOptionPlanMember 2022-01-01 2022-09-30 0001360214 HROW:StockOptionPlanMember 2022-07-01 2022-09-30 0001360214 HROW:StockOptionPlanMember 2021-07-01 2021-09-30 0001360214 HROW:StockOptionPlanMember 2021-01-01 2021-09-30 0001360214 HROW:UnvestedRSUMember 2022-09-30 0001360214 HROW:UnvestedRSUMember 2022-01-01 2022-09-30 0001360214 HROW:UnvestedRSUMember 2022-07-01 2022-09-30 0001360214 HROW:UnvestedRSUMember 2021-07-01 2021-09-30 0001360214 HROW:UnvestedRSUMember 2021-01-01 2021-09-30 0001360214 HROW:SubsidiaryStockMember 2022-07-01 2022-09-30 0001360214 HROW:SubsidiaryStockMember 2022-01-01 2022-09-30 0001360214 HROW:SubsidiaryStockMember 2021-07-01 2021-09-30 0001360214 HROW:SubsidiaryStockMember 2021-01-01 2021-09-30 0001360214 HROW:StockOptionPlanOneMember 2021-12-31 0001360214 HROW:StockOptionPlanOneMember 2022-01-01 2022-09-30 0001360214 HROW:StockOptionPlanOneMember 2022-09-30 0001360214 HROW:OptionsEmployeesMember 2022-01-01 2022-09-30 0001360214 srt:MinimumMember HROW:OptionsEmployeesMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember HROW:OptionsEmployeesMember 2022-01-01 2022-09-30 0001360214 HROW:RangeOneMember 2022-01-01 2022-09-30 0001360214 HROW:RangeOneMember 2022-09-30 0001360214 HROW:RangeTwoMember 2022-01-01 2022-09-30 0001360214 HROW:RangeTwoMember 2022-09-30 0001360214 HROW:RangeThreeMember 2022-01-01 2022-09-30 0001360214 HROW:RangeThreeMember 2022-09-30 0001360214 HROW:RangeFourMember 2022-01-01 2022-09-30 0001360214 HROW:RangeFourMember 2022-09-30 0001360214 HROW:RangeFiveMember 2022-01-01 2022-09-30 0001360214 HROW:RangeFiveMember 2022-09-30 0001360214 HROW:RangeSixMember 2022-01-01 2022-09-30 0001360214 HROW:RangeSixMember 2022-09-30 0001360214 HROW:RangeSevenMember 2022-01-01 2022-09-30 0001360214 HROW:RangeSevenMember 2022-09-30 0001360214 HROW:RangeEightMember 2022-01-01 2022-09-30 0001360214 HROW:RangeEightMember 2022-09-30 0001360214 HROW:RangeNineMember 2022-01-01 2022-09-30 0001360214 HROW:RangeNineMember 2022-09-30 0001360214 HROW:RangeTenMember 2022-01-01 2022-09-30 0001360214 HROW:RangeTenMember 2022-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001360214 us-gaap:WarrantMember 2021-12-31 0001360214 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001360214 us-gaap:WarrantMember 2022-09-30 0001360214 HROW:LenderWarrantsMember 2022-01-01 2022-09-30 0001360214 HROW:LenderWarrantsMember 2022-09-30 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001360214 HROW:EmployeesMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001360214 HROW:EmployeesMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001360214 srt:DirectorMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001360214 HROW:ConsultantMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001360214 HROW:ConsultantMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001360214 HROW:ConsultantMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001360214 HROW:ConsultantMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:KlarityLicenseAgreementMember 2022-07-01 2022-09-30 0001360214 HROW:KlarityLicenseAgreementMember 2022-01-01 2022-09-30 0001360214 HROW:KlarityLicenseAgreementMember 2021-07-01 2021-09-30 0001360214 HROW:KlarityLicenseAgreementMember 2021-01-01 2021-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2022-07-01 2022-09-30 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2022-01-01 2022-09-30 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2021-07-01 2021-09-30 0001360214 HROW:InjectableAssetPurchaseAgreementMember 2021-01-01 2021-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:PresbyopiaAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2022-07-01 2022-09-30 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2022-01-01 2022-09-30 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2021-07-01 2021-09-30 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2021-01-01 2021-09-30 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2022-09-30 0001360214 HROW:PresbyopiaAssetPurchaseAgreementMember 2021-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2022-07-01 2022-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2022-01-01 2022-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2021-07-01 2021-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2021-01-01 2021-09-30 0001360214 HROW:SinteticaAgreementMember 2021-07-01 2021-07-31 0001360214 HROW:DueWithinThirtyDaysMember HROW:SinteticaAgreementMember 2021-07-01 2021-07-31 0001360214 us-gaap:ResearchAndDevelopmentExpenseMember HROW:SinteticaAgreementMember 2021-01-01 2021-12-31 0001360214 HROW:WakamotoAgreementMember 2021-08-01 2021-08-31 0001360214 HROW:DexycuAgreementMember 2022-07-01 2022-09-30 0001360214 HROW:DexycuAgreementMember 2022-01-01 2022-09-30 0001360214 HROW:DexycuAgreementMember 2021-07-01 2021-09-30 0001360214 HROW:DexycuAgreementMember 2021-01-01 2021-09-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2022-01-01 2022-09-30 0001360214 srt:MinimumMember HROW:SalesAndMarketingAgreementsMember 2022-01-01 2022-09-30 0001360214 srt:MaximumMember HROW:SalesAndMarketingAgreementsMember 2022-01-01 2022-09-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2022-07-01 2022-09-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2021-07-01 2021-09-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2021-01-01 2021-09-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-09-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2022-07-01 2022-09-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2022-01-01 2022-09-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2021-07-01 2021-09-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2021-01-01 2021-09-30 0001360214 us-gaap:WarrantMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001360214 us-gaap:WarrantMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-31 0001360214 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001360214 us-gaap:OptionMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001360214 srt:MinimumMember us-gaap:OptionMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001360214 srt:MaximumMember us-gaap:OptionMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0001360214 us-gaap:SubsequentEventMember HROW:AssetPurchaseAgreementMember 2022-10-01 2022-10-30 0001360214 us-gaap:SubsequentEventMember HROW:AssetPurchaseAgreementMember 2022-10-30 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001360214 false Q3 --12-31 P1Y 10-Q true 2022-09-30 2022 false 001-35814 Harrow Health, Inc. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Common Stock, $0.001 par value per share HROW NASDAQ 8.625% Senior Notes due 2026 HROWL NASDAQ Yes Yes Non-accelerated Filer true false false 27413654 44959000 42167000 4162000 8503000 6743000 4470000 5283000 4217000 2927000 1305000 64074000 60662000 3291000 3141000 1878000 1313000 7688000 5935000 19632000 15813000 2097000 11133000 332000 332000 98992000 98329000 14112000 6337000 3441000 3089000 115000 16000 703000 272000 8000 18371000 9722000 7520000 6012000 10000 72239000 71654000 98130000 87398000 0.001 0.001 50000000 50000000 27074307 27074307 26902763 26902763 27000 27000 111738000 106666000 -110548000 -95407000 1217000 11286000 -355000 -355000 862000 10931000 98992000 98329000 21575000 17811000 63433000 50056000 1248000 900000 4833000 2232000 22823000 18711000 68266000 52288000 6721000 4947000 19218000 13134000 16102000 13764000 49048000 39154000 15421000 11356000 43004000 28643000 775000 6125000 2347000 7142000 16196000 17481000 45351000 35785000 -94000 -3717000 3697000 3369000 1800000 1685000 5386000 3512000 3504000 706000 9036000 2967000 -1031000 -2220000 -4341000 -8639000 -756000 1967000 -51000 -6335000 -4611000 -18763000 -13958000 -6429000 -8328000 -15066000 -10589000 35000 75000 -6464000 -8328000 -15141000 -10589000 472000 -6464000 -8328000 -15141000 -11061000 -0.24 -0.31 -0.55 -0.42 27349642 27112531 27293756 26626722 25749875 26000 104557000 -77400000 27183000 -355000 26828000 311369 25480 65000 65000 65000 1207500 1000 -1000 391461 -3228000 -3228000 -3228000 440000 10655000 10655000 10655000 440000 11000000 11000000 11000000 127000 127000 127000 3630000 3630000 3630000 -10589000 -10589000 -10589000 26902763 27000 104551000 -87989000 16589000 -355000 16234000 26902763 27000 106666000 -95407000 11286000 -355000 10931000 4054 92261 7000 7000 7000 185000 1000 -1000 109771 -1000 -875000 -876000 -876000 5941000 5941000 5941000 -15141000 -15141000 -15141000 27074307 27000 111738000 -110548000 1217000 -355000 862000 26893896 27000 102837000 -79661000 23203000 -355000 22848000 8867 17000 17000 17000 1697000 1697000 1697000 -8328000 -8328000 -8328000 26902763 27000 104551000 -87989000 16589000 -355000 16234000 27069978 27000 109806000 -104084000 5749000 -355000 5394000 4054 275 1932000 1932000 1932000 -6464000 -6464000 -6464000 27074307 27000 111738000 -110548000 1217000 -355000 862000 -15141000 -10589000 1090000 1275000 1200000 122000 435000 422000 36000 36000 585000 480000 1967000 -4341000 -8639000 9036000 2967000 136000 706000 5941000 3630000 2309000 1532000 1066000 -37000 716000 866000 1534000 2983000 352000 428000 99000 -63000 5417000 6572000 9827000 19000 75000 12592000 1719000 1649000 -1738000 -4489000 18000 5000 71073000 15961000 876000 3228000 7000 65000 10655000 11000000 127000 -887000 51472000 2792000 53555000 42167000 4301000 44959000 57856000 44959000 57656000 200000 44959000 57856000 75000 4851000 2603000 1000 5000000 86000 906000 2188000 1753000 908000 <p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zCuBydR605C9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_827_znGQ0Zkfiinb">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company and Background</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company owns non-controlling equity positions in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow consolidates entities in which it has a controlling financial interest. The Company assesses control under the variable interest entity (“VIE”) model to determine whether the Company is the primary beneficiary of that entity’s operations. The Company consolidates (i) entities in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights, and (ii) entities that the Company deems to be a VIE. All intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_z6leVkZnZH0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2. <span id="xdx_821_zgNMHBe6OzRa">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following represents an update for the three and nine months ended September 30, 2022 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zef4eZCS8ra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_z2ZE5wigVRYd">Risks, Uncertainties and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zhZOIEvcvPlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zK2wJFe6KDZg">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of shifts in the Company’s strategic plans to further focus on growing the Company’s ImprimisRx business and suspension of activities related to starting up development-stage pharmaceutical companies, along with changes to the Company’s organizational and internal reporting structure, beginning in January 2022, management no longer evaluates the Company’s business in two segments and instead focuses on the performance of the business as a single operating business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zQOPVivzUVia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zm9h8YWpBn09">Basic and Diluted Net Loss per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs and warrants were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zop2HKH02qsb" title="Antidilutive securities">5,622,997</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zeStefXTypAg" title="Antidilutive securities">5,657,046</span> at September 30, 2022 and 2021, respectively. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at September 30, 2022 and 2021 was <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNCVhWIjn4S1" title="Number of shares vestted, RSUs">303,454</span> and <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zarK4Ibvxcrd" title="Number of shares vestted, RSUs">258,117</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zv9Q8GNxj027" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the computation of basic net loss per share of common stock for the three and nine months ended September 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zPlDqFQ7zuUb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49D_20220701__20220930_zEGrSpFtVfN8" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49C_20210701__20210930_zPQoPnHQnx4k" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_490_20220101__20220930_zq63EiJX6m6i" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_493_20210101__20210930_zYZHn1G9E7l9" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_zWsS6K7P8Xdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net loss attributable to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(6,464,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(8,328,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(15,141,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(10,589,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zNOnsh9ikfuc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,349,642</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,112,531</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,293,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,626,722</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_z6DYzj4Rtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.24</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.31</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A4_zuOwhDxtpTO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_eus-gaap--InvestmentPolicyTextBlock_z4O5w7d1uwFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zR9cFVBgxrF7">Investment in Eton Pharmaceuticals, Inc</span>. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company owned <span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zm4Y4qoDBEA7" title="Investment owned balance shares">1,982,000</span> shares of Eton common stock, which represents less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z6lm3v070Oi4" title="Ownership percentage">10</span>% of the equity interests of Eton. At September 30, 2022, the fair market value of Eton’s common stock was $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z8TFSESDXE79" title="Shares price">2.10</span> per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>, the Company recorded an unrealized investment loss from its Eton common stock position of $<span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20220701__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zfkRLwo3hUb2" title="Unrealized gain loss on investments">1,031,000</span> and $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zH4eqLXlyW3e" title="Unrealized gain loss on investments">4,341,000</span>, and $<span id="xdx_90D_eus-gaap--UnrealizedGainLossOnInvestments_c20210701__20210930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zhlAT5V9Zkec" title="Unrealized gain loss on investments">2,220,000</span> and $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zdutQDqT6N18" title="Unrealized gain loss on investments">8,639,000</span> during the three and nine months ended September 30, 2022 and 2021, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of September 30, 2022, the fair market value of the Company’s investment in Eton was $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z9wRXoSPfks7" title="Investment owned, at fair value">4,162,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--InvestmentOnePolicyTextBlock_zhJ2sqdksU9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zb9ckgOg4g39">Investment in Melt Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zz7LSppjwRu6" title="Number of shares owned">3,500,000</span> shares of common stock of Melt (representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zD3C5eCkdNOb" title="Ownership percentage">46</span>% of the equity interests as of September 30, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its common stock investment in Melt to $<span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zO5I2nhcdtzd" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of September 30, 2022 and at the time of entering into the Melt Loan Agreement (see Note 4), the Company owned <span id="xdx_90C_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zdPm1UWAfyA9" title="Investment interest rate">100</span>% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInCommonStockInvestment_c20220101__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zcMU7tWFmtO2" title="Reduction in common stock investment">0</span>, the Company began recording <span id="xdx_90C_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zTsalyLMa611" title="Investment interest rate">100</span>% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other requirements to advance funds to Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_897_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zH8KG5bqh7ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investments in Melt as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUoAkK1SQ1K3" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center">In-substance</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost<br/> Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Share of Equity <br/> Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Paid-in-Kind<br/> Interest</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital <br/> Contributions</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying <br/> value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQZKDnjvZH94" style="width: 10%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpFbNsF3DGyh" style="width: 12%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zo2y5o8wylT7" style="width: 10%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"/><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRSVY3a5OSPh" style="border-bottom: Black 1pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOYKfFcSFGo9" style="border-bottom: Black 1pt solid; text-align: right" title="Share of Equity Method Losses">(11,403,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--InvestmentPaidInKindInterest_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z0n8mliIVK3h" style="border-bottom: Black 1pt solid; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb6j1J3MxL6j" style="border-bottom: Black 1pt solid; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zAw7jB2leltb" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zvEvZkGLd768" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVEGOkiN1EV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(17,213,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJrb1j6gp4of" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb1dxxsllvmk" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zyonxHSbugNd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_z5tG6rwO7Ru9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 for more information and related party disclosure regarding Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--InvestmentRelatedPartyPolicyTextBlock_zT8zJvVF3f6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zc9mFTVSGU9k">Investment in Surface Ophthalmics, Inc. – Related Party</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zDpKeJRo3hcb" title="Number of shares owned">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zuDnFCw4F492" title="Equity method investment ownership, percentage">20</span>% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_903_ecustom--ReductionInCommonStockInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zKDY5tBYwvd4" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znAZ5iXAplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investment in Surface as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zs18sS7Vv6ob" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Cost</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Share of Equity</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zbaasrqBoKli" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zrG7Rp3ToGZ5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1BLIruSIu5e" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zhF7Kc9WbGV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 5 for more information and related party disclosure regarding Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_ze3FUxeyTCve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuELD6ifYO07">Impairment of Equity Method Investments and Note Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments and note receivable. At September 30, 2022 and December 31, 2021, no indicators of impairment existed.</span></p> <p id="xdx_852_zHen2q3SJSz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zef4eZCS8ra3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_z2ZE5wigVRYd">Risks, Uncertainties and Liquidity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zhZOIEvcvPlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zK2wJFe6KDZg">Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of shifts in the Company’s strategic plans to further focus on growing the Company’s ImprimisRx business and suspension of activities related to starting up development-stage pharmaceutical companies, along with changes to the Company’s organizational and internal reporting structure, beginning in January 2022, management no longer evaluates the Company’s business in two segments and instead focuses on the performance of the business as a single operating business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zQOPVivzUVia" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zm9h8YWpBn09">Basic and Diluted Net Loss per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Common equivalent shares (using the treasury stock method) from stock options, unvested RSUs and warrants were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zop2HKH02qsb" title="Antidilutive securities">5,622,997</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_zeStefXTypAg" title="Antidilutive securities">5,657,046</span> at September 30, 2022 and 2021, respectively. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at September 30, 2022 and 2021 was <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNCVhWIjn4S1" title="Number of shares vestted, RSUs">303,454</span> and <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zarK4Ibvxcrd" title="Number of shares vestted, RSUs">258,117</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zv9Q8GNxj027" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the computation of basic net loss per share of common stock for the three and nine months ended September 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zPlDqFQ7zuUb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49D_20220701__20220930_zEGrSpFtVfN8" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49C_20210701__20210930_zPQoPnHQnx4k" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_490_20220101__20220930_zq63EiJX6m6i" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_493_20210101__20210930_zYZHn1G9E7l9" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_zWsS6K7P8Xdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net loss attributable to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(6,464,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(8,328,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(15,141,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(10,589,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zNOnsh9ikfuc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,349,642</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,112,531</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,293,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,626,722</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_z6DYzj4Rtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.24</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.31</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A4_zuOwhDxtpTO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5622997 5657046 303454 258117 <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zv9Q8GNxj027" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table shows the computation of basic net loss per share of common stock for the three and nine months ended September 30, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zPlDqFQ7zuUb" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49D_20220701__20220930_zEGrSpFtVfN8" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49C_20210701__20210930_zPQoPnHQnx4k" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_490_20220101__20220930_zq63EiJX6m6i" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_493_20210101__20210930_zYZHn1G9E7l9" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2022</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_zWsS6K7P8Xdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net loss attributable to common stockholders</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(6,464,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(8,328,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(15,141,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(10,589,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_zNOnsh9ikfuc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Denominator – weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,349,642</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,112,531</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">27,293,756</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,626,722</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--EarningsPerShareBasic_pid_z6DYzj4Rtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.24</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.31</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.55</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -6464000 -8328000 -15141000 -10589000 27349642 27112531 27293756 26626722 -0.24 -0.31 -0.55 -0.42 <p id="xdx_845_eus-gaap--InvestmentPolicyTextBlock_z4O5w7d1uwFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zR9cFVBgxrF7">Investment in Eton Pharmaceuticals, Inc</span>. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company owned <span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zm4Y4qoDBEA7" title="Investment owned balance shares">1,982,000</span> shares of Eton common stock, which represents less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z6lm3v070Oi4" title="Ownership percentage">10</span>% of the equity interests of Eton. At September 30, 2022, the fair market value of Eton’s common stock was $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z8TFSESDXE79" title="Shares price">2.10</span> per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>, the Company recorded an unrealized investment loss from its Eton common stock position of $<span id="xdx_90C_eus-gaap--UnrealizedGainLossOnInvestments_c20220701__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zfkRLwo3hUb2" title="Unrealized gain loss on investments">1,031,000</span> and $<span id="xdx_90A_eus-gaap--UnrealizedGainLossOnInvestments_c20220101__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zH4eqLXlyW3e" title="Unrealized gain loss on investments">4,341,000</span>, and $<span id="xdx_90D_eus-gaap--UnrealizedGainLossOnInvestments_c20210701__20210930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zhlAT5V9Zkec" title="Unrealized gain loss on investments">2,220,000</span> and $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20210101__20210930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_zdutQDqT6N18" title="Unrealized gain loss on investments">8,639,000</span> during the three and nine months ended September 30, 2022 and 2021, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of September 30, 2022, the fair market value of the Company’s investment in Eton was $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EtonPharmaceuticalsIncMember_z9wRXoSPfks7" title="Investment owned, at fair value">4,162,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1982000 0.10 2.10 1031000 4341000 2220000 8639000 4162000 <p id="xdx_847_ecustom--InvestmentOnePolicyTextBlock_zhJ2sqdksU9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zb9ckgOg4g39">Investment in Melt Pharmaceuticals, Inc. – Related Party</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zz7LSppjwRu6" title="Number of shares owned">3,500,000</span> shares of common stock of Melt (representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zD3C5eCkdNOb" title="Ownership percentage">46</span>% of the equity interests as of September 30, 2022). The Company analyzes its investment in Melt and related agreements on a regular basis to evaluate its position of variable interests in Melt. The Company has determined that it does not have the ability to control Melt, however it has the ability to exercise significant influence over the operating and financial decisions of Melt and uses the equity method of accounting for this investment. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced the carrying value of its common stock investment in Melt to $<span id="xdx_906_ecustom--ReductionInCommonStockInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zO5I2nhcdtzd" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses in Melt since its deconsolidation in 2019. As of September 30, 2022 and at the time of entering into the Melt Loan Agreement (see Note 4), the Company owned <span id="xdx_90C_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zdPm1UWAfyA9" title="Investment interest rate">100</span>% of Melt’s indebtedness. Following the reduction of the carrying value of the Company’s common stock investment in Melt to $<span id="xdx_901_ecustom--ReductionInCommonStockInvestment_c20220101__20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zcMU7tWFmtO2" title="Reduction in common stock investment">0</span>, the Company began recording <span id="xdx_90C_eus-gaap--InvestmentInterestRate_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--MeltPharmaceuticalsIncMember_zTsalyLMa611" title="Investment interest rate">100</span>% of the equity method losses of Melt, based on its ownership of Melt’s total indebtedness. In addition, the Company treats interest paid in kind on the Melt Loan Agreement as an in-substance capital contribution and reduces its investment in Melt accordingly, rather than recording interest income. The Company has no other requirements to advance funds to Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p id="xdx_897_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zH8KG5bqh7ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investments in Melt as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUoAkK1SQ1K3" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center">In-substance</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost<br/> Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Share of Equity <br/> Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Paid-in-Kind<br/> Interest</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital <br/> Contributions</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying <br/> value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQZKDnjvZH94" style="width: 10%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpFbNsF3DGyh" style="width: 12%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zo2y5o8wylT7" style="width: 10%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"/><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRSVY3a5OSPh" style="border-bottom: Black 1pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOYKfFcSFGo9" style="border-bottom: Black 1pt solid; text-align: right" title="Share of Equity Method Losses">(11,403,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--InvestmentPaidInKindInterest_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z0n8mliIVK3h" style="border-bottom: Black 1pt solid; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb6j1J3MxL6j" style="border-bottom: Black 1pt solid; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zAw7jB2leltb" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zvEvZkGLd768" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVEGOkiN1EV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(17,213,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJrb1j6gp4of" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb1dxxsllvmk" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zyonxHSbugNd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_z5tG6rwO7Ru9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 for more information and related party disclosure regarding Melt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3500000 0.46 0 1 0 1 <p id="xdx_897_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zH8KG5bqh7ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investments in Melt as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zUoAkK1SQ1K3" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center"/><td> </td><td> </td> <td colspan="2" style="text-align: center">In-substance</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cost<br/> Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Share of Equity <br/> Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Paid-in-Kind<br/> Interest</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Capital <br/> Contributions</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Carrying <br/> value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: justify">Common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQZKDnjvZH94" style="width: 10%; text-align: right" title="Cost basis">5,810,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpFbNsF3DGyh" style="width: 12%; text-align: right" title="Share of Equity Method Losses">(5,810,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zo2y5o8wylT7" style="width: 10%; text-align: right" title="Paid in Kind Interest"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"/><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Loan</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--InvestmentOwnedAtCost_iI_pp0p0_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zRSVY3a5OSPh" style="border-bottom: Black 1pt solid; text-align: right" title="Cost basis">13,500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_pp0p0_di_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOYKfFcSFGo9" style="border-bottom: Black 1pt solid; text-align: right" title="Share of Equity Method Losses">(11,403,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--InvestmentPaidInKindInterest_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z0n8mliIVK3h" style="border-bottom: Black 1pt solid; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb6j1J3MxL6j" style="border-bottom: Black 1pt solid; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__custom--LoanMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zAw7jB2leltb" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zvEvZkGLd768" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost Basis">19,310,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zVEGOkiN1EV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share of Equity Method Losses">(17,213,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--InvestmentPaidInKindInterest_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zJrb1j6gp4of" style="border-bottom: Black 2.5pt double; text-align: right" title="Paid in Kind Interest">1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentCompanyCommittedCapital_iN_di_c20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb1dxxsllvmk" style="border-bottom: Black 2.5pt double; text-align: right" title="In Substance Capital Contributions">(1,995,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Investments_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zyonxHSbugNd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying Value">2,097,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5810000 5810000 13500000 11403000 1995000 1995000 2097000 19310000 17213000 1995000 1995000 2097000 <p id="xdx_84C_ecustom--InvestmentRelatedPartyPolicyTextBlock_zT8zJvVF3f6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zc9mFTVSGU9k">Investment in Surface Ophthalmics, Inc. – Related Party</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns <span id="xdx_908_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zDpKeJRo3hcb" title="Number of shares owned">3,500,000</span> common shares of Surface (representing approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zuDnFCw4F492" title="Equity method investment ownership, percentage">20</span>% of Surface’s equity interests following the closing of a round of financing completed by Surface in July 2021) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. During the year ended December 31, 2021, the Company reduced its common stock investment in Surface to $<span id="xdx_903_ecustom--ReductionInCommonStockInvestment_c20210101__20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SurfaceOphthalmicsIncMember_zKDY5tBYwvd4" title="Reduction in common stock investment">0</span> as a result of the Company recording its share of equity losses of Surface. The Company has no other investments in Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znAZ5iXAplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investment in Surface as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zs18sS7Vv6ob" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Cost</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Share of Equity</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zbaasrqBoKli" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zrG7Rp3ToGZ5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1BLIruSIu5e" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zhF7Kc9WbGV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 5 for more information and related party disclosure regarding Surface.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 3500000 0.20 0 <p id="xdx_89F_eus-gaap--InvestmentTableTextBlock_hdei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_znAZ5iXAplLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s investment in Surface as of September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zs18sS7Vv6ob" style="display: none">SCHEDULE OF INVESTMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Cost</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Share of Equity</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Basis</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Method Losses</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Carrying value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 42%; text-align: justify; padding-bottom: 2.5pt">Common stock</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentOwnedAtCost_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zbaasrqBoKli" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Cost Basis">5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentAggregateCost_iNI_di_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zrG7Rp3ToGZ5" style="border-bottom: Black 2.5pt double; width: 18%; text-align: right" title="Share of Equity Method Losses">(5,320,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Investments_iI_c20220930__us-gaap--InvestmentTypeAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z1BLIruSIu5e" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Net carrying value"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5320000 5320000 <p id="xdx_84B_eus-gaap--EquityMethodInvestmentsPolicy_ze3FUxeyTCve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuELD6ifYO07">Impairment of Equity Method Investments and Note Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On a quarterly basis, management assesses whether there are any indicators that the carrying value of the Company’s equity method investments and note receivable may be other than temporarily impaired. Indicators include financial condition, operating performance, and near-term prospects of the investee. To the extent indicators suggest that a loss in value may have occurred, the Company will evaluate both quantitative and qualitative factors to determine if the loss in value is other than temporary. If a potential loss in value is determined to be other than temporary, the Company will recognize an impairment loss based on the estimated fair value of the equity method investments and note receivable. At September 30, 2022 and December 31, 2021, no indicators of impairment existed.</span></p> <p id="xdx_804_eus-gaap--RevenueFromContractWithCustomerTextBlock_zAcwKXk4neN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3. <span id="xdx_826_zTbxePFPnORk">REVENUES </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for contracts with customers in accordance with Accounting Standards Codification (“ASC”) 606, <i>Revenues from Contracts with Customers</i>. The Company has three primary streams of revenue: (1) revenue recognized from sales of products through its pharmacy and outsourcing facility and sales of branded products to wholesalers through a third-party logistics (“3PL”) partner, (2) revenue recognized from a commission agreement with a third party, and (3) revenue recognized from intellectual property licenses and asset purchase agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Product Revenues </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s pharmacy services includes: (i) the portion of the price the client pays directly to the Company, net of any volume-related or other discounts paid back to the client, (ii) the price paid to the Company by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, the Company has identified the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the contract(s) with a customer</i>: A contract is deemed to exist when the customer places an order through receipt of a prescription, via an online order or via receipt of a purchase order from a customer. For branded products, orders are received through the Company’s 3PL partner, and the customer takes title of the products via formal purchase orders placed and fulfilled.</span></td></tr> </table> <p style="margin: 0"> </p> <p style="margin: 0"/> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the performance obligations in the contract:</i> Obligations for fulfillment of the Company’s contracts consist of delivering the product to customers at their specified destination. ASU 2016-10 was issued in April 2016 and amended ASC 606 for shipping and handling activities as follows: If the customer takes control of the goods after shipment, shipping and handling activities would always be considered a fulfillment activity and not treated as a separate performance obligation. If the customer takes control of the goods before shipment, entities must make an accounting policy election to treat shipping and handling activities as either a fulfillment cost or as a separate performance obligation. The Company has elected to treat its shipping and handling activities as a fulfillment cost.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determine the transaction price:</i> The transaction price is based on an amount that reflects the consideration to which the Company expects to be entitled, net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively, sales deductions) and an estimate for returns and replacements established at the time of sale. The Company utilizes the services of a third-party professional services firm to estimate rebates and chargebacks associated with sales of its branded products. The transfer of promised goods is satisfied within a year, and therefore there are no significant financing components. There is no non-cash consideration related to product sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocate the transaction price to the performance obligations in the contract:</i> Given that there is only one performance obligation for product sales, no allocation is necessary.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize revenue when (or as) the entity satisfies a performance obligation:</i> Revenue from products is recognized upon transfer of control of a product to a customer. This generally occurs upon shipment unless contractual terms with a customer state that transfer of control occurs at delivery.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Commission Revenues</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into an agreement whereby it is paid a fee calculated based on sales the Company generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues From Transfer of Acquired Product Profit </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company <span style="background-color: white">entered into an agreement whereby it purchased the exclusive commercial rights to assets associated with certain ophthalmic products from another pharmaceutical company (the “Seller”). During a temporary, six month transition period, the Seller continued </span>to manufacture and market these products and transfer the net profit from the sale of the products to the Company. The revenue recognized by the Company from the transfer of net profit was recognized at the time profit from the product sales were calculated by the Seller and confirmed by the Company, typically on a monthly basis, at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the Company’s part to recognize the associated revenue. On a quarterly basis, the Seller invoiced the Company for all credits and reimbursements (“Chargebacks”) made to customers related to the products. The Company used historical actual experience to estimate Chargebacks associated with the net profit transferred. The estimate is recorded as a reduction in revenues in the Company’s condensed consolidated statements of operations and accounts receivable in the condensed consolidated balance sheets at the time the revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual Property License Revenues</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently holds five intellectual property licenses and related agreements pursuant to which the Company has agreed to license or sell to a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time that the performance obligation is met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zj3Yxl7BjU65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue disaggregated by revenue source for the three and nine months ended September 30, 2022 and 2021 consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B9_zamvVVX5mxUi">SCHEDULE OF DISAGGREGATED REVENUE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220701__20220930_zrhNCYz2hoq2" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210701__20210930_zSgZYguSJkPb" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220101__20220930_zjk8WzRChfle" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20210930_zXanv1uWUbVb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zA3SsSmWOR4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">21,575,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">17,811,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">63,433,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,056,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_z2UHslTlotre" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Commission revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,576,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,212,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zJWSHNj9YXZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Transfer of profits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,257,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zVO79uRhv0eb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">License revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,823,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,711,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,266,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,288,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z4LwTF3QH5fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue and customer deposits at September 30, 2022 and December 31, 2021 were $<span id="xdx_907_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20220930_ze65Sxejdyd7" title="Contract with customer liability current">115,000</span> and $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_c20211231_zF7Dn3ftKN6d" title="Contract with customer liability current">16,000</span>, respectively. All deferred revenue and customer deposit amounts at December 31, 2021 were recognized as revenue during the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--DisaggregationOfRevenueTableTextBlock_zj3Yxl7BjU65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue disaggregated by revenue source for the three and nine months ended September 30, 2022 and 2021 consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B9_zamvVVX5mxUi">SCHEDULE OF DISAGGREGATED REVENUE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220701__20220930_zrhNCYz2hoq2" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210701__20210930_zSgZYguSJkPb" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20220101__20220930_zjk8WzRChfle" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20210101__20210930_zXanv1uWUbVb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ProductSalesNetMember_zA3SsSmWOR4g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">21,575,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">17,811,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">63,433,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,056,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CommissionsMember_z2UHslTlotre" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Commission revenues</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,044,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,576,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,212,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TransferOfProfitMember_zJWSHNj9YXZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Transfer of profits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">204,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,257,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--LicenseMember_zVO79uRhv0eb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">License revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,823,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,711,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">68,266,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,288,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 21575000 17811000 63433000 50056000 1044000 900000 3576000 2212000 204000 1257000 10000 20000 22823000 18711000 68266000 52288000 115000 16000 <p id="xdx_800_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zOR7U5RF3I7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4. <span id="xdx_821_z0NsbtBChVCc">INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In February 2019, the Company and Melt entered into a Management Service Agreement between the Company and Melt (the “Melt MSA”), whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly amount of $<span id="xdx_909_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zc0OV8DbcX34" title="Administrative fees expense">10,000</span>. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and nine months ended September 30, 2022, the Company recorded $<span id="xdx_903_eus-gaap--OtherExpenses_c20220701__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zb69ZMhrqpl4" title="Reimbursable expenses">30,000</span> and $<span id="xdx_90E_eus-gaap--OtherExpenses_c20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2aOtLfzcN22" title="Reimbursable expenses">100,000</span>, respectively, due from Melt for reimbursable expenses and amounts payable pursuant to the Melt MSA, which are included in prepaid expenses and other current assets in the accompanying condensed consolidated balance sheets. <span style="background-color: white">As of September 30, 2022 and December 31, 2021, the Company was due $<span id="xdx_907_eus-gaap--DueFromRelatedParties_iI_c20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zQPjYRk47Sub" title="Due from Related Parties">139,000</span> and $<span id="xdx_90B_eus-gaap--DueFromRelatedParties_iI_c20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zpMmqa5MSAj" title="Due from Related Parties">48,000</span>, respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three and nine months ended September 30, 2022. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s Chief Executive Officer, Mark L. Baum, was previously a member of the Melt board of directors until his resignation during the year ended December 31, 2021. Following Mr. Baum’s departure, the Company no longer has any representation on Melt’s board of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zlVI6nhPChfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed results of operations information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zJSaSaKIVPq2" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49B_20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKUyAiPrqPki" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_499_20210101__20210930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z06z1v94Y23k" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_znJRnUqLrmmj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zgE1SfvzSIs9" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(9,064,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(3,765,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zpubiJsFd2G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,562,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,907,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A2_zRVSpm6dtWsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zkhnaorIRZ42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed balance sheet information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zkfB5j7AfEib" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_494_20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zYeHFvAyhxgf" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_498_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXCrL6wKrA2d" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zkZ2p8SB7LU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,638,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,278,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zgyEUpxlwSOa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">994,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Assets_iI_zI2iAecWsOv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,632,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Liabilities_iI_zxknHnCyZIae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,207,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15,732,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zSd7V6728uw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,575,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,454,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zCEtPQxReZt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,632,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z9UxdxnSLtxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Melt Note Receivable</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, the Company entered into a loan and security agreement in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zLrel1XhkPfa" title="Face amount">13,500,000</span> (the “Melt Loan Agreement”), as lender, with Melt, as borrower. Amounts borrowed under the Melt Loan Agreement bear interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zTgSsSXjVu8h" title="Debt instrument interest rate, stated percentage">12.50</span>% per annum, which interest can be paid in-kind at the option of Melt until the maturity date. The Melt Loan Agreement permits Melt to pay interest only on the principal amount loaned thereunder through the term and all amounts owed were previously due and payable on September 1, 2022. In April 2022, the Company entered into a First Amendment and in September 2022, a Second Amendment (together, the “Amendments”) to the Melt Loan Agreement. The Amendments (i) extended the maturity date of the Melt Loan Agreement to June 1, 2023, which can be extended further to September 1, 2026 upon Melt completing a qualifying financing of a minimum amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_z8fNc0yfyAm9" title="Loan amount">10,000,000</span> from third-party investors, (ii) added conditions related to minimum cash amounts following a qualifying financing, and (iii) clarified the definition of material adverse effects. Melt may elect to prepay all, but not less than all, of the amounts owed prior to the maturity date at any time without penalty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melt has granted the Company a security interest in substantially all of its personal property, rights and assets, including intellectual property rights, to secure the payment of all amounts owed under the Melt Loan Agreement. The Melt Loan Agreement contains customary representations, warranties and covenants, including covenants by Melt limiting additional indebtedness, liens, mergers and acquisitions, dispositions, investments, distributions, subordinated debt, and transactions with affiliates. The Melt Loan Agreement includes customary events of default, and upon the occurrence of an event of default (subject to cure periods for certain events of default), all amounts owed by Melt thereunder may be declared immediately due and payable by the Company, and the interest rate on the loan may be increased by <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_c20210829__20210901__us-gaap--TypeOfArrangementAxis__custom--MeltLoanAgreementMember_zppU6ZBUe55a" title="Increase in interest rate">3</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Melt Loan Agreement, the Company and Melt entered into a Right of First Refusal Agreement providing the Company with the right, but not the obligation, to match any offer received by Melt associated with the commercial rights to any of Melt’s drug candidates for a period of five years following the effective date of the Melt Loan Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net funds received by Melt excluded $<span id="xdx_906_ecustom--AccountsReceivableTransferredToNoteReceivable_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzFD1YmQEiYh" title="Accounts receivable transferred to note receivable">908,000</span> owed to the Company for reimbursable expenses and amounts due under the Melt MSA prior to the effective date of the note receivable. As of September 30, 2022 and December 31, 2021, $<span id="xdx_90C_eus-gaap--NotesReceivableRelatedParties_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zotgYXfNPUXd" title="Notes receivable related parties">15,495,000</span> and $<span id="xdx_90F_eus-gaap--NotesReceivableRelatedParties_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zgEw92U1h7Gh" title="Notes receivable related parties">14,076,000</span>, respectively, in principal balance of the Melt Loan Agreement is payable to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000 30000 100000 139000 48000 <p id="xdx_896_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zlVI6nhPChfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed results of operations information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zJSaSaKIVPq2" style="display: none">SCHEDULE OF CONDENSED INCOME STATEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49B_20220101__20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zKUyAiPrqPki" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_499_20210101__20210930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z06z1v94Y23k" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_znJRnUqLrmmj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0935">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zgE1SfvzSIs9" style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(9,064,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(3,765,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zpubiJsFd2G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10,562,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,907,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -9064000 -3765000 -10562000 -3907000 <p id="xdx_89C_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zkhnaorIRZ42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed balance sheet information of Melt is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zkfB5j7AfEib" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_494_20220930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zYeHFvAyhxgf" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_498_20211231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zXCrL6wKrA2d" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--AssetsCurrent_iI_zkZ2p8SB7LU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,638,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">11,278,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsNoncurrent_iI_zgyEUpxlwSOa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">994,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Assets_iI_zI2iAecWsOv5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,632,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--Liabilities_iI_zxknHnCyZIae" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,207,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15,732,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--StockholdersEquity_iI_zSd7V6728uw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(14,575,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,454,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zCEtPQxReZt3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,632,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,278,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3638000 11278000 994000 4632000 11278000 19207000 15732000 -14575000 -4454000 4632000 11278000 13500000 0.1250 10000000 0.03 908000 15495000 14076000 <p id="xdx_809_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_zraQDHD7Cish" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5. <span id="xdx_825_zc1tRmS3Kpqj">INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company owned <span id="xdx_907_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20220930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z2sDeAKtKbLa" title="Investment owned balance shares">3,500,000</span> shares of Surface common stock. Company directors Richard L. Lindstrom, Perry J. Sternberg and Mark L. Baum, who is also the Company’s Chief Executive Officer, are directors of Surface. Dr. Lindstrom is a principal of Flying L Partners, an affiliate of an investor who purchased Surface Series A Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zL7GJEMgP0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed results of operations information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zhSMmBL660w3" style="display: none">SUMMARY OF CONDENSED INCOME STATEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_498_20220101__20220930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z0TbSduK3IWk" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49E_20210101__20210930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zmt1GwXCYeza" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKJkqYd15Aeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zYaGIHAYWjVf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(5,338,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(6,859,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zEb1Ox83hXIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,338,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,859,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AE_z2oUDhfg00Cb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znsmt8MuMU4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed balance sheet information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zMY2rWmMSjs5" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_495_20220930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zHwF2LFipkLj" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_490_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z77YadhUzt7e" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsCurrent_iI_zjZjbvOmSKl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">16,625,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">21,731,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_iI_z6vw8j7fmjfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">661,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">412,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Assets_iI_zt0VrgvtZFl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,286,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Liabilities_iI_zTsdXPe8jbjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,745,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,514,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zBKvznd0Clie" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,541,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,629,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zJGQwNdjxgYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,286,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zkXMvRFjC9Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3500000 <p id="xdx_899_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zL7GJEMgP0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed results of operations information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zhSMmBL660w3" style="display: none">SUMMARY OF CONDENSED INCOME STATEMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_498_20220101__20220930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z0TbSduK3IWk" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_49E_20210101__20210930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zmt1GwXCYeza" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Nine Months Ended<br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zKJkqYd15Aeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zYaGIHAYWjVf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(5,338,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(6,859,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zEb1Ox83hXIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,338,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,859,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -5338000 -6859000 -5338000 -6859000 <p id="xdx_89F_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_znsmt8MuMU4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed balance sheet information of Surface is summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zMY2rWmMSjs5" style="display: none">SUMMARY OF CONDENSED BALANCE SHEET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_495_20220930__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_zHwF2LFipkLj" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_490_20211231__dei--LegalEntityAxis__custom--SurfaceOphthalmicsIncMember_z77YadhUzt7e" style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">At </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--AssetsCurrent_iI_zjZjbvOmSKl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">16,625,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">21,731,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AssetsNoncurrent_iI_z6vw8j7fmjfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Non-current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">661,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">412,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Assets_iI_zt0VrgvtZFl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,286,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Liabilities_iI_zTsdXPe8jbjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,745,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,514,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquity_iI_zBKvznd0Clie" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total preferred stock and stockholders’ deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15,541,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,629,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iI_zJGQwNdjxgYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,286,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,143,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 16625000 21731000 661000 412000 17286000 22143000 1745000 1514000 15541000 20629000 17286000 22143000 <p id="xdx_801_eus-gaap--InventoryDisclosureTextBlock_zUWwFmwuhPod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6. <span id="xdx_82C_z82IR4y20AMg">INVENTORIES </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfoaf0CmFxy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded commercial pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of September 30, 2022 and December 31, 2021 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_ztmpzv4NWPub" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220930_zjyfuDI3USw" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20211231_zAKYUiX282E7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_zvu1jtddoyh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,507,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zuRY5eNpmNSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maCzfns_z99KQgPSqic9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,776,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtCzfns_zLcDSFpd8nle" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,283,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,217,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zdLe7K79725i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zfoaf0CmFxy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, branded commercial pharmaceutical products, including those held at the Company’s 3PL partner, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of September 30, 2022 and December 31, 2021 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_ztmpzv4NWPub" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49C_20220930_zjyfuDI3USw" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20211231_zAKYUiX282E7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_maCzfns_zvu1jtddoyh4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,507,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,441,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryWorkInProcess_iI_maCzfns_zuRY5eNpmNSd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maCzfns_z99KQgPSqic9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,776,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InventoryNet_iTI_mtCzfns_zLcDSFpd8nle" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,283,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,217,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3507000 2441000 26000 1750000 1776000 5283000 4217000 <p id="xdx_804_eus-gaap--OtherAssetsDisclosureTextBlock_zaA4xrRjAaUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7. <span id="xdx_82D_zCnyQm9s7oG3">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zqIFiqyyH9ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zOCbH9r3DDfc" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220930_zIou5VverVQi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20211231_zK2wuqNbLsVe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidInsurance_iI_maCz7yK_zYAFxOhmO1R5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">728,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidRoyalties_iI_maCz7yK_zsM4zCJKtp8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid computer software licenses and related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">781,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DueFromRelatedParties_iI_maCz7yK_zQRnhk30NQI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Due from Melt Pharmaceuticals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_z4UIYSB8eTFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">769,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zhXpQY0KObll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">92,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zdj1mnlL9Uei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,927,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,305,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zQcOKP1sMJZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zqIFiqyyH9ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zOCbH9r3DDfc" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20220930_zIou5VverVQi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_499_20211231_zK2wuqNbLsVe" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidInsurance_iI_maCz7yK_zYAFxOhmO1R5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">728,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidRoyalties_iI_maCz7yK_zsM4zCJKtp8h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid computer software licenses and related expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">781,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DueFromRelatedParties_iI_maCz7yK_zQRnhk30NQI2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Due from Melt Pharmaceuticals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherPrepaidExpenseCurrent_iI_maCz7yK_z4UIYSB8eTFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">769,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAssetsCurrent_iI_maCz7yK_zhXpQY0KObll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Deposits and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">92,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtCz7yK_zdj1mnlL9Uei" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,927,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,305,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1165000 728000 781000 248000 139000 48000 769000 189000 73000 92000 2927000 1305000 <p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zMk70Kuj3D6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8.<span id="xdx_826_zvhqlzNnrzX3"> PROPERTY, PLANT AND EQUIPMENT </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrTlEKK7wGS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zJgflMCYqA75" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220930_z8f97fNowFC4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20211231_zD8lpCKgLlPd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zX6nN3TP3BMi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Computer hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">875,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">772,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_zPFXGj8ZNAb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">843,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zAvwUwBy5q55" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,160,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,056,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zvDyNKw8tPZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,276,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,703,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zrOnDA5DEKFi" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,154,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,974,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_z4kgda4pYQS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,863,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,833,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_zKsOJN9EEwbh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,291,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,141,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zfTo1fgjI9gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2022, depreciation related to the property, plant and equipment was $<span id="xdx_903_eus-gaap--Depreciation_c20220701__20220930_z5FaqFOaTIgc" title="Depreciation">171,000</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20220101__20220930_z4lg7mHgjoHf" title="Depreciation">928,000</span>, respectively, compared to $<span id="xdx_90C_eus-gaap--Depreciation_c20210701__20210930_zZGVFtQ3gbmb" title="Depreciation">410,000</span> and $<span id="xdx_903_eus-gaap--Depreciation_c20210101__20210930_ziNQ9sFDOos6" title="Depreciation">1,202,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrTlEKK7wGS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zJgflMCYqA75" style="display: none">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20220930_z8f97fNowFC4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">September 30, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20211231_zD8lpCKgLlPd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, <br/> 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ComputerHardwareGross_iI_maCzxAW_maPPAEGz2wu_zX6nN3TP3BMi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Computer hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">875,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">772,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FurnitureAndFixturesGross_iI_maCzxAW_maPPAEGz2wu_zPFXGj8ZNAb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">843,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MachineryAndEquipmentGross_iI_maCzxAW_maPPAEGz2wu_zAvwUwBy5q55" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,160,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,056,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LeaseholdImprovementsGross_iI_maCzxAW_maPPAEGz2wu_zvDyNKw8tPZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,276,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,703,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtPPAEGz2wu_maPPAENz062_zrOnDA5DEKFi" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,154,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,974,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzNSh_msPPAENz062_z4kgda4pYQS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(8,863,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,833,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz062_zKsOJN9EEwbh" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,291,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,141,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 875000 772000 843000 443000 4160000 4056000 6276000 5703000 12154000 10974000 8863000 7833000 3291000 3141000 171000 928000 410000 1202000 <p id="xdx_805_ecustom--CapitalizedSoftwareDevelopmentCostsTextBlock_zLyHxpkoR2Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9. <span id="xdx_828_zjJGpSc5FLhi">CAPITALIZED SOFTWARE DEVELOPMENT COSTS </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfCapitalizedSoftwareDevelopmentCostsTableTextBlock_zradI26utSxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software development costs at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z41cDhsqNl06" style="display: none">SCHEDULE OF CAPITALIZED SOFTWARE DEVELOPMENT COSTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220930_zwuwTu0ju5m4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30, <br/> 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20211231_zcA9njFQVhWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, <br/> 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zePRGTM9wjVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 60%; text-align: left"><span style="font-size: 10pt">Capitalized internal-use software development costs</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">1,533,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">417,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_z15kuCUJvH61" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Acquired third-party software license for internal-use</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">159,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">684,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzmFw_maCCSNzzzb_zja7Ux7PgLIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total gross capitalized software for internal-use</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,692,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,101,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCzmFw_msCCSNzzzb_z9CLx538rBO" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left"><span style="font-size: 10pt">Accumulated amortization</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">(731,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">(569,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_407_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCzmFw_maCCSNzzzb_zSSL9lHmq2k1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Capitalized internal-use software in process</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">917,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">781,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzzzb_zLl70VNIzpF5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Capitalized software costs, net</span><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,878,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,313,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A9_zMmDoCSyCSD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded amortization expense of $<span id="xdx_900_eus-gaap--AdjustmentForAmortization_c20220701__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zNtjUBK59tnl" title="Amortization expense">76,000</span> and $<span id="xdx_908_eus-gaap--AdjustmentForAmortization_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zt09gEC0Njgc" title="Amortization expense">162,000</span> related to capitalized software development costs during the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_901_eus-gaap--AdjustmentForAmortization_c20210701__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zVnynffIdDKe" title="Amortization expense">22,000</span> and $<span id="xdx_909_eus-gaap--AdjustmentForAmortization_c20210101__20210930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedSoftwareDevelopmentCostsMember_zXjrj2S9Ev35" title="Amortization expense">73,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--ScheduleOfCapitalizedSoftwareDevelopmentCostsTableTextBlock_zradI26utSxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized software development costs at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z41cDhsqNl06" style="display: none">SCHEDULE OF CAPITALIZED SOFTWARE DEVELOPMENT COSTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220930_zwuwTu0ju5m4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30, <br/> 2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49E_20211231_zcA9njFQVhWb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, <br/> 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CapitalizedInternalUseSoftwareMember_zePRGTM9wjVc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 60%; text-align: left"><span style="font-size: 10pt">Capitalized internal-use software development costs</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">1,533,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">417,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThirdPartySoftwareLicenseMember_z15kuCUJvH61" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Acquired third-party software license for internal-use</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">159,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">684,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzmFw_maCCSNzzzb_zja7Ux7PgLIg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total gross capitalized software for internal-use</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,692,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,101,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCzmFw_msCCSNzzzb_z9CLx538rBO" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left"><span style="font-size: 10pt">Accumulated amortization</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">(731,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">(569,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_407_ecustom--CapitalizedComputerSoftwareInternalUseInProcess_iI_maCzmFw_maCCSNzzzb_zSSL9lHmq2k1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Capitalized internal-use software in process</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">917,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">781,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNzzzb_zLl70VNIzpF5" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Capitalized software costs, net</span><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,878,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,313,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 1533000 417000 159000 684000 1692000 1101000 731000 569000 917000 781000 1878000 1313000 76000 162000 22000 73000 <p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zlKhVP4wDjxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10. <span id="xdx_82E_zC6nmy2hu1Ud">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zDvbTlnPIFE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets at September 30, 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z7SrxSkFeg1d" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Periods</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Cost</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">Impairment</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%"><span style="font-size: 10pt">Patents</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGjMVKMwfTmb" title="Useful life">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zRjFONnCZ01i" title="Useful life">19</span> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z82GoF9K4e45" style="width: 10%; text-align: right" title="Cost"><span style="font-size: 10pt">981,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQpg8alJA9Uf" style="width: 10%; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(140,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zFdKa1QaFGcg" style="width: 10%; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zoMNvwGzCCvk" style="width: 10%; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">841,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Licenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zV197DqpuNOl" title="Useful life">20</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zK29YAEwT7sh" style="text-align: right" title="Cost"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z6Rc7yAN3mU4" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfQaoOwLG4Vk" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zsMYxo9P9FUk" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">80,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Trademarks</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0eHPGsgfZJi" title="Useful life, description">Indefinite</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zuh3YkReRvAe" style="text-align: right" title="Cost"><span style="font-size: 10pt">264,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z7N6k4yeF4W6" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zYy0DYUAHWb8" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPcGJsYGl699" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">264,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Acquired NDAs</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zzZpgb0KC9ff" title="Useful life">10</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zfJIgJkRFnyf" style="text-align: right" title="Cost"><span style="font-size: 10pt">18,635,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zsXl3CU8Bxu" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(1,023,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zM9yeEPeVg7c" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zokpV8uNrAF8" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">17,612,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Customer relationships</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8p6lIxvSiAb">3</span>-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z9kFhOjIavc3" title="Useful life">15</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2MnFe3XfBA9" style="text-align: right" title="Cost"><span style="font-size: 10pt">1,519,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zo3pt8E5Tcph" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(685,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoSUJUpCjZ37" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zgAZDubXxSNc" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">834,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Trade name</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zKUN4EnMaH69" title="Useful life">5</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQe6sVwJnle4" style="text-align: right" title="Cost"><span style="font-size: 10pt">5,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zx95zLtDcAN2" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(5,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQwoA8irRi4f" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zc9BncwYVNb" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Non-competition clause</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z85JVT0avwUh" title="Useful life">3</span>-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziNoJmxbRq8e" title="Useful life">4</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z1qIJNA2E7nf" style="text-align: right" title="Cost"><span style="font-size: 10pt">50,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z6rCizzOkfib" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(50,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_znVpI3ILAmLa" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zWqm8qeLoiN3" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">State pharmacy licenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z4UbQ4xUKVJg" title="Useful life">25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zTYhjbjkXl4e" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"><span style="font-size: 10pt">8,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zDgnVBFsSmha" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(7,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zktdlV90egoe" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zrdsMt1ZFhs" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">1,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930_zSo9FWVKTIB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-size: 10pt">21,562,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930_zBztF93VRq3b" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(1,930,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930_z45izWHLC8R7" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930_z6rw459B9dw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">19,632,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_z17YTFl6AeMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zv9lRucRk623" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for intangible assets for the three and nine months ended September 30, 2022 and 2021 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zuWP65N21nm2" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220701__20220930_z3eD6xS2WcNh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210701__20210930_zkBwqmvBMOe5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220101__20220930_zhMvRU7lDjY1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210101__20210930_zvasgSEhbVn7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Nine Months Ended</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVZFI4EiMX5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%"><span style="font-size: 10pt">Patents</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">22,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">8,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">65,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNIycqxCpvug" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Licenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zTNy0h5K6x2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Acquired NDAs</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">341,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,023,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zKVIqMCriHw6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Customer relationships</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">33,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">34,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">99,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">398,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">43,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,200,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">122,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zQVO56yQQRV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztxcxjrOdZ13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated future amortization expense for the Company’s intangible assets at September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zTSpsIZRGbcc" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220930_zrzE1DvHhPeb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANz2X3_zbUPRhkpADa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">523,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz2X3_zM0040t2hJh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz2X3_zqO89ndmHJVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz2X3_zOVsKYSApgDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz2X3_zpcFoKsLCt92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,096,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANz2X3_znahdRLPHPh1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">10,473,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz2X3_zSmFKsIkLCy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">19,368,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zxOYfTKFwV29" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zDvbTlnPIFE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets at September 30, 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_z7SrxSkFeg1d" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Periods</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Cost</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span></p></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><span style="font-size: 10pt">Impairment</span></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carrying Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%"><span style="font-size: 10pt">Patents</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGjMVKMwfTmb" title="Useful life">17</span>-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zRjFONnCZ01i" title="Useful life">19</span> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z82GoF9K4e45" style="width: 10%; text-align: right" title="Cost"><span style="font-size: 10pt">981,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQpg8alJA9Uf" style="width: 10%; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(140,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zFdKa1QaFGcg" style="width: 10%; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1125">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zoMNvwGzCCvk" style="width: 10%; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">841,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Licenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zV197DqpuNOl" title="Useful life">20</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zK29YAEwT7sh" style="text-align: right" title="Cost"><span style="font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z6Rc7yAN3mU4" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(20,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfQaoOwLG4Vk" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zsMYxo9P9FUk" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">80,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Trademarks</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0eHPGsgfZJi" title="Useful life, description">Indefinite</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zuh3YkReRvAe" style="text-align: right" title="Cost"><span style="font-size: 10pt">264,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z7N6k4yeF4W6" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zYy0DYUAHWb8" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1145">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPcGJsYGl699" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">264,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Acquired NDAs</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zzZpgb0KC9ff" title="Useful life">10</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zfJIgJkRFnyf" style="text-align: right" title="Cost"><span style="font-size: 10pt">18,635,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zsXl3CU8Bxu" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(1,023,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zM9yeEPeVg7c" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zokpV8uNrAF8" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">17,612,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Customer relationships</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8p6lIxvSiAb">3</span>-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z9kFhOjIavc3" title="Useful life">15</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2MnFe3XfBA9" style="text-align: right" title="Cost"><span style="font-size: 10pt">1,519,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zo3pt8E5Tcph" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(685,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoSUJUpCjZ37" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zgAZDubXxSNc" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt">834,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Trade name</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zKUN4EnMaH69" title="Useful life">5</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQe6sVwJnle4" style="text-align: right" title="Cost"><span style="font-size: 10pt">5,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zx95zLtDcAN2" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(5,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zQwoA8irRi4f" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zc9BncwYVNb" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1178">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Non-competition clause</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z85JVT0avwUh" title="Useful life">3</span>-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_ziNoJmxbRq8e" title="Useful life">4</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z1qIJNA2E7nf" style="text-align: right" title="Cost"><span style="font-size: 10pt">50,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_z6rCizzOkfib" style="text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(50,000</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_znVpI3ILAmLa" style="text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zWqm8qeLoiN3" style="text-align: right" title="Net Carrying value"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">State pharmacy licenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20220101__20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z4UbQ4xUKVJg" title="Useful life">25</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zTYhjbjkXl4e" style="border-bottom: Black 1pt solid; text-align: right" title="Cost"><span style="font-size: 10pt">8,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zDgnVBFsSmha" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(7,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zktdlV90egoe" style="border-bottom: Black 1pt solid; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zrdsMt1ZFhs" style="border-bottom: Black 1pt solid; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">1,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_c20220930_zSo9FWVKTIB8" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-size: 10pt">21,562,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_c20220930_zBztF93VRq3b" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-size: 10pt">(1,930,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pp0p0_c20220930_z45izWHLC8R7" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pp0p0_c20220930_z6rw459B9dw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-size: 10pt">19,632,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> P17Y P19Y 981000 -140000 841000 P20Y 100000 -20000 80000 Indefinite 264000 264000 P10Y 18635000 -1023000 17612000 P3Y P15Y 1519000 -685000 834000 P5Y 5000 -5000 P3Y P4Y 50000 -50000 P25Y 8000 -7000 1000 21562000 -1930000 19632000 <p id="xdx_895_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zv9lRucRk623" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization expense for intangible assets for the three and nine months ended September 30, 2022 and 2021 was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zuWP65N21nm2" style="display: none">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220701__20220930_z3eD6xS2WcNh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20210701__20210930_zkBwqmvBMOe5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220101__20220930_zhMvRU7lDjY1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210101__20210930_zvasgSEhbVn7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Three Months Ended</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Nine Months Ended</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zVZFI4EiMX5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%"><span style="font-size: 10pt">Patents</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">22,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">8,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">65,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 10pt">20,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zNIycqxCpvug" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Licenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">13,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NewDrugApplicationsMember_zTNy0h5K6x2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Acquired NDAs</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">341,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,023,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zKVIqMCriHw6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Customer relationships</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">33,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">34,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">99,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">100,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">398,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">43,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,200,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">122,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 22000 8000 65000 20000 2000 1000 13000 2000 341000 1023000 33000 34000 99000 100000 398000 43000 1200000 122000 <p id="xdx_891_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ztxcxjrOdZ13" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated future amortization expense for the Company’s intangible assets at September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zTSpsIZRGbcc" style="display: none">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20220930_zrzE1DvHhPeb" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANz2X3_zbUPRhkpADa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">523,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANz2X3_zM0040t2hJh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANz2X3_zqO89ndmHJVb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANz2X3_zOVsKYSApgDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,092,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANz2X3_zpcFoKsLCt92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">2,096,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANz2X3_znahdRLPHPh1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">10,473,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANz2X3_zSmFKsIkLCy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">19,368,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 523000 2092000 2092000 2092000 2096000 10473000 19368000 <p id="xdx_802_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zTFEP6OJXlib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11. <span id="xdx_82E_zlIQ9aUNKXMb">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zMv6K8VWIpfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zlG5qOsAmxjd" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220930_zSKAyEMtlHic" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20211231_zKJp4XdZgUsh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maCzhNV_zN60Lt6OQzdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-size: 10pt">Accounts payable</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">7,043,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">5,174,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maCzhNV_zXZpGw3xVJd9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Accrued insurance premium</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">906,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maCzhNV_zhJTc1pAHH57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Accrued IHEEZO milestone payment</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">5,000,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maCzhNV_zGQCUweEGZk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Other accrued expenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">49,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">49,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maCzhNV_zXuROqCzvkr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtCzhNV_z8yydH92EgW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total accounts payable and accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">14,112,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">6,337,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zIi4ORGkjTbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company financed all insurance policies for the policy term of August 17, 2022 through August 16, 2023. The financing agreement has an interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zCJpyLzLnkXa" title="Debt instrument interest rate, during period">4.13</span>% per annum and requires eight monthly payments of $<span id="xdx_908_ecustom--AccruedMonthlyPayments_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9u5GQMFfAEc" title="Accrued monthly payments">114,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zMv6K8VWIpfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses at September 30, 2022 and December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zlG5qOsAmxjd" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20220930_zSKAyEMtlHic" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20211231_zKJp4XdZgUsh" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">September 30,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31,</span></td><td style="font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maCzhNV_zN60Lt6OQzdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-size: 10pt">Accounts payable</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">7,043,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 16%; text-align: right"><span style="font-size: 10pt">5,174,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maCzhNV_zXZpGw3xVJd9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Accrued insurance premium</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">906,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrentAndNoncurrent_iI_maCzhNV_zhJTc1pAHH57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Accrued IHEEZO milestone payment</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">5,000,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maCzhNV_zGQCUweEGZk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Other accrued expenses</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">49,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">49,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maCzhNV_zXuROqCzvkr" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Accrued interest</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtCzhNV_z8yydH92EgW5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total accounts payable and accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">14,112,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">6,337,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 7043000 5174000 906000 5000000 49000 49000 1114000 1114000 14112000 6337000 0.0413 114000 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zvUYLJGNIECi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12. <span id="xdx_828_zuk5lzPTgVea">DEBT </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>8.625% Senior Notes Due 2026 </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, the Company closed an offering of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zAYlx0R0G2ek" title="Face amount">50,000,000</span> aggregate principal amount of 8.625% senior notes due April 2026, and in May 2021 issued an additional $<span id="xdx_908_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zT5JXAbqaZw" title="Debt instrument increase decrease period for net">5,000,000</span> of such notes pursuant to the full exercise of the underwriters’ option to purchase additional notes (collectively, the “April Notes”). The April Notes were sold to investors at a par value of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zsENqixykLZ6" title="Shares issued price per share">25.00</span> per April Note and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20210401__20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zagSNWjQlOV" title="Proceeds from issuance of debt">51,909,000</span> after deducting underwriting discounts and commissions and expenses of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210430__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zAIxLxzmr27h" title="Deducting underwriting discounts and commissions and expenses">3,091,000</span>. In June 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zObycwgoh2Si" title="Debt instrument increase decrease for period net">20,000,000</span> aggregate principal amount of such notes (the “June Notes,” and together with the April Notes, the “Notes”), at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zDsdwShFSHUl" title="Shares issued price per share">25.75</span> per June Note, with interest of $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zUbWtEBb254h" title="Interest expense debt">278,000</span> on the June Notes being accrued from April 20, 2021 as of the date of issuance. The June offering resulted in net proceeds to the Company of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfDebt_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zzuqCsEZdhq" title="Proceeds from issuance of debt">19,164,000</span> after deducting underwriting discounts and commissions and expenses of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20210630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zEwVcW0Vd4di" title="Deducting underwriting discounts and commissions and expenses">1,158,000</span> and a premium on note issuance of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedPremium_iI_c20210630__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z6Z6k9NIBVfd" title="Debt instrument unamortized premium">322,000</span>. The June Notes are treated as a single series with the April Notes under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the initial offering price and issue date). <span style="background-color: white">T</span>he Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The Notes bear interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zzFVe9hW8PVb" title="Interest rate, during period">8.625</span>% per annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The Notes will mature on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zTFbILmah4Gk" title="Debt instrument maturity date">April 30, 2026</span>. The <span style="background-color: white">issuance costs were recorded as a debt discount and are being amortized as interest expense, net of the amortization of the premium on note issuance, over the term of the Notes using the effective interest rate method.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a <span id="xdx_90C_eus-gaap--DebtInstrumentRedemptionDescription_c20260130__20260131__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zJKeuWTGZvl2" title="Redemption description">redemption price equal to 100% of the principal amount of the Notes to be redeemed</span>, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense related to the Notes totaled $<span id="xdx_90A_eus-gaap--InterestExpenseOtherLongTermDebt_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zzanhr3QZaKc" title="Interest expense other than long term debt">1,814,000</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseOtherLongTermDebt_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zT5b2DA89wOd" title="Interest expense other than long term debt">5,436,000</span> for the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_90B_eus-gaap--InterestExpenseOtherLongTermDebt_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zu0zcXiJnRW1" title="Interest expense other than long term debt">1,464,000</span> and $<span id="xdx_906_eus-gaap--InterestExpenseOtherLongTermDebt_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_z80D5Ng6gq57" title="Interest expense other than long term debt">2,930,000</span> during the three and nine months ended September 30, 2021, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220701__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zhVPgAftgnld" title="Amortization of financing costs and discount">197,000</span> and $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zuy4PQFHKQTd" title="Amortization of financing costs and discount">585,000</span> for three and nine months ended September 30, 2022, respectively, and $<span id="xdx_905_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210701__20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zwBsvgbjpzgl" title="Amortization of financing costs and discount">197,000</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_c20210101__20210930__us-gaap--LongtermDebtTypeAxis__custom--SeniorNotesDueTwoThousandTwentySixMember_zELUgWtBINAg" title="Amortization of financing costs and discount">389,000</span> during the three and nine months ended September 30, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zkBNTILsZoq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At September 30, 2022, future minimum payments under the Company’s debt were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zKmRDThZfWhc" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20220930_zzl4iabdPfq4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzgXJ_zPTz1wcBr8ek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">1,617,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zpheZ9fLu3Af" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_zSkFQrjEM8S6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_zZThgm0vFHPb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzgXJ_zmkRqLxaAERe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">2026</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">77,158,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zZMZTmtmhto7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Total minimum payments</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">98,182,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_z3C6JZfGLh5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing interest payments</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(23,182,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zbRy2tVzkgh8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Notes payable, gross</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">75,000,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zswqGDztTfDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: unamortized discount, net of premium</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(2,761,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--LongTermNotesPayable_iI_zQz4J1D1i8A" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Notes payable, net of unamortized discount</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">72,239,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AE_zwejukp5luLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50000000 5000000 25.00 51909000 3091000 20000000 25.75 278000 19164000 1158000 322000 0.08625 2026-04-30 redemption price equal to 100% of the principal amount of the Notes to be redeemed 1814000 5436000 1464000 2930000 197000 585000 197000 389000 <p id="xdx_89C_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zkBNTILsZoq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At September 30, 2022, future minimum payments under the Company’s debt were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zKmRDThZfWhc" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENT UNDER NOTES PAYABLES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_492_20220930_zzl4iabdPfq4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzgXJ_zPTz1wcBr8ek" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">1,617,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzgXJ_zpheZ9fLu3Af" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzgXJ_zSkFQrjEM8S6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzgXJ_zZThgm0vFHPb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">6,469,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzgXJ_zmkRqLxaAERe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">2026</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">77,158,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebt_iTI_mtCzgXJ_zZMZTmtmhto7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Total minimum payments</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">98,182,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--InterestPayableCurrent_iNI_di_z3C6JZfGLh5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing interest payments</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(23,182,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_zbRy2tVzkgh8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Notes payable, gross</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">75,000,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_zswqGDztTfDl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: unamortized discount, net of premium</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(2,761,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_409_eus-gaap--LongTermNotesPayable_iI_zQz4J1D1i8A" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Notes payable, net of unamortized discount</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">72,239,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 1617000 6469000 6469000 6469000 77158000 98182000 23182000 75000000 -2761000 72239000 <p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_z2Kvp3ZP5U33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13. <span id="xdx_82E_zRiRResorY3">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have remaining terms between <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dxL_c20220930__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zbhhkNryRDn9" title="Lease term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1349">one</span></span> to <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zYwqbln2AJJd" title="Lease term">five years</span> and contain various clauses for renewal at the Company’s option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An operating lease for <span id="xdx_90B_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220930__srt--StatementGeographicalAxis__custom--CarlsbadMember_zsovRsn5Ljg8" title="Area of land">5,789</span> square feet of office space in Carlsbad, California, which commenced in January 2022 and will expire in <span id="xdx_908_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220930__srt--StatementGeographicalAxis__custom--CarlsbadMember_zwgaN6Y73cWi" title="Lease expiration date, description">July 2027</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An operating lease for <span id="xdx_901_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220930__srt--StatementGeographicalAxis__custom--LedgewoodMember_zNlXuNrqAvTb" title="Area of land">35,326</span> square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in <span id="xdx_903_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220930__srt--StatementGeographicalAxis__custom--LedgewoodMember_zrrsUDtpzzKe" title="Lease expiration date, description">July 2026</span>, with an option to extend the term for two additional five-year periods. This lease was amended, effective July 2020, to extend the term of the original lease and add <span id="xdx_908_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220930__srt--StatementGeographicalAxis__custom--LedgewoodMember_z5gYrQFeiNEl" title="Area of land">1,400</span> of additional square footage to the lease, and amended again in May 2021 to extend the term of the lease to July 2027 and add <span id="xdx_90A_ecustom--AdditionalAreaOfLand_uSquareFoot_c20220101__20220930__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAmendmentMember_zNWCWUYM7uS3" title="Area of land">8,900</span> square feet of space.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An operating lease for <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220930__srt--StatementGeographicalAxis__custom--NashvilleMember_zWGRoQaXHHVe" title="Area of land">5,500</span> square feet of office space in Nashville, Tennessee that expires in <span id="xdx_906_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220930__srt--StatementGeographicalAxis__custom--NashvilleMember_zAPRGHCmqYkd" title="Lease expiration date, description">December 2024</span>, with an option to extend the term for two additional five-year periods.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An operating lease for <span id="xdx_905_eus-gaap--AreaOfLand_iI_uSquareFoot_c20220930__srt--StatementGeographicalAxis__custom--Nashville1Member_zBiDf8e0R9d4" title="Area of land">11,552</span> square feet of lab and office space in Nashville, Tennessee which commenced in June 2022 and expires in<span id="xdx_906_ecustom--LeaseExpirationDateDescription_dd_c20220101__20220930__srt--StatementGeographicalAxis__custom--Nashville1Member_zvHT3MkJf9F1" title="Lease expiration date, description"> June 2027</span>.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2022, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were <span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20220930_zvUM5hPwCKc5" title="Weighted average discount rate percent">6.62</span>% and <span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220930_zPRB3Xf9jgzg" title="Lease term">10.99</span> years, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and nine months ended September 30, 2022, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220701__20220930_z9jWzFm2Xh2j" title="Operating lease payments">249,000</span> and $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20220101__20220930_zfvHnxrHi2A9" title="Operating lease payments">622,000</span>, respectively, and $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20210701__20210930_z1zqgPtJ0UF7" title="Operating lease payments">250,000</span> and $<span id="xdx_90A_eus-gaap--OperatingLeasePayments_c20210101__20210930_zuHPkYBWYGpe" title="Operating lease payments">752,000</span> during the same periods in 2021, respectively. During the three and nine months ended September 30, 2022, the Company recorded operating lease expense of $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20220701__20220930_zG0fFgrF8LN2" title="Operating lease expense">309,000</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20220101__20220930_zTDtw0qE7fRb" title="Operating lease expense">809,000</span>, respectively, which is included in selling, general and administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIKEqU4tSOf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future lease payments under operating leases as of September 30, 2022 were as follows<b>: </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> <span id="xdx_8B1_zHAgmxnYk9j2" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220930_zJNLU5w0Gtb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Operating Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzv0z_zn4wao2vp0z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">303,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zc3IUMi4OmH6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,231,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_zDmYpwKIoJzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,262,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_ziV9z2lhxmA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,093,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zdQWExH33uhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_z689ZxQrA0z9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">6,801,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_zYqJOdz33YV8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Total minimum lease payments</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">11,804,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCLqcVdMM5F6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing interest payments</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(3,581,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zZeE6dPZF2Zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-size: 10pt">Total operating lease liabilities</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">8,223,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zdOM2T0TKt2h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: current portion, operating lease liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(703,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Operating lease liabilities, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">7,520,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_z3vdCbvL4P3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company repaid all remaining amounts owed under its finance lease and no future payments are due related to finance leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y 5789 July 2027 35326 July 2026 1400 8900 5500 December 2024 11552 June 2027 0.0662 P10Y11M26D 249000 622000 250000 752000 309000 809000 <p id="xdx_89E_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zIKEqU4tSOf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future lease payments under operating leases as of September 30, 2022 were as follows<b>: </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> <span id="xdx_8B1_zHAgmxnYk9j2" style="display: none">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20220930_zJNLU5w0Gtb6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Operating Leases</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzv0z_zn4wao2vp0z2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-size: 10pt">Remainder of 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 20%; text-align: right"><span style="font-size: 10pt">303,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv0z_zc3IUMi4OmH6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2023</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,231,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv0z_zDmYpwKIoJzc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2024</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,262,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv0z_ziV9z2lhxmA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">2025</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,093,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzv0z_zdQWExH33uhi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">2026</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">1,114,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_maLOLLPzv0z_z689ZxQrA0z9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">6,801,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv0z_zYqJOdz33YV8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Total minimum lease payments</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">11,804,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCLqcVdMM5F6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: amount representing interest payments</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(3,581,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zZeE6dPZF2Zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-size: 10pt">Total operating lease liabilities</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">8,223,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zdOM2T0TKt2h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Less: current portion, operating lease liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(703,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Operating lease liabilities, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">7,520,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 303000 1231000 1262000 1093000 1114000 6801000 11804000 3581000 8223000 703000 7520000 <p id="xdx_806_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zqpqDQRfBP0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14. <span id="xdx_82A_zvSivoiQH0r">STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2022 and December 31, 2021, the Company had <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20220930_zQDZ7JGIVuIj" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zNWUNARlAtO9" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock, $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220930_zjpXtHVkOTm2" title="Preferred stock, par or stated value per share"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zWdo7Zq3f6kk" title="Preferred stock, par or stated value per share">0.001</span></span> par value, authorized and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20220930_z8n6zckK1yB5" title="Preferred stock, shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20220930_zwYA6seU7jw7" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231_zeVPvUejblg6" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zbPbYON3NXv2" title="Preferred stock, shares issued">no</span></span></span></span> shares of preferred stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zgRQkdKGZMm6" title="Number of common stock issued">53,594</span> shares of common stock to Mark L. Baum, the Company’s Chief Executive Officer, upon the cashless exercise of options to purchase <span id="xdx_90A_ecustom--CashlessExerciseOfOptionsShares_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zecPLvlSZJMf" title="Cashless exercise of options, shares">125,000</span> shares at an exercise price of $<span id="xdx_903_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_z7XklrmMDg87" title="Cashless exercise of options, price per shares">2.40</span> per share. The Company withheld from Mr. Baum <span id="xdx_90E_ecustom--CommonStockWithheldOnCashlessExercise_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zXebIfHn9Rjl" title="Common stock withheld on cashless exercise">36,014</span> shares as consideration for the cashless exercise and an additional <span id="xdx_901_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zIVoUbrQS9j1" title="Common stock withheld for payroll tax withholdings, shares">35,392</span> shares for payroll tax obligations totaling $<span id="xdx_908_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkLBaumMember_zoqareixtVpf" title="Common stock withheld for payroll tax withholdings, value">295,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zmLfnZjWkCL4" title="Number of common stock issued">4,054</span> shares of common stock to consultants upon the cashless exercise of options to purchase <span id="xdx_90A_ecustom--CashlessExerciseOfOptionsShares_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zPiXyudVvw1b" title="Cashless exercise of options, shares">15,995</span> shares at an exercise price of $<span id="xdx_90A_ecustom--CashlessExerciseOfOptionsPricePerShares_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_z7zzYsFwr1Gi" title="Cashless exercise of options, price per shares">7.07</span> per share. The Company withheld <span id="xdx_908_ecustom--CommonStockWithheldOnCashlessExercise_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zhYn6E8KdZC8" title="Common stock withheld on cashless exercise">11,941</span> shares as consideration for the cashless exercise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zt6ckyXf4SWb" title="Exercise of option, shares">3,275</span> shares of common stock and received net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zBlag5uWrE9e" title="Proceeds from stock option exercise">7,000</span> upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zradxNUZD6p4" title="Exercise of option, shares">3,275</span> shares of common stock with exercise prices between $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MinimumMember_zZb3SXGyImh" title="Exercise Price">1.70</span> to $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MaximumMember_zjMlIGNKQ9f5" title="Exercise Price">3.95</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zCERLab5RIhl" title="Number of restricted stock units granted">50,000</span> RSUs granted in February 2019 to Andrew R. Boll, the Company’s Chief Financial Officer, vested, and in February 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zCQiNf8FqNih" title="Number of common stock issued">29,395</span> shares of common stock to Mr. Boll, net of <span id="xdx_90F_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_za62TYHzO25" title="Common stock withheld for payroll tax withholdings, shares">20,605</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_905_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AndrewRBollMember_zPZRWu94WQDd" title="Common stock withheld for payroll tax withholdings, value">162,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zxepPogrfdH4" title="Number of restricted stock units granted">50,000</span> RSUs granted in February 2019 to John P. Saharek, the President of ImprimisRx, vested, and in February 2022, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zb0hToP2Y6D3" title="Number of common stock issued">24,077</span> shares of common stock to Mr. Saharek, net of <span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zgYzc4v412Qa" title="Common stock withheld for payroll tax withholdings, shares">25,923</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnPSaharekMember_zZiZcXE5pUB1" title="Common stock withheld for payroll tax withholdings, value">204,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--VestingAxis__custom--FebruaryTwoThousandNineteenMember_zyMlhrDRTe3c" title="Number of restricted stock units granted">35,000</span> RSUs granted in February 2019 vested, and in February 2022, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYpf6VmaoHRj" title="Number of common stock issued">20,298</span> shares of common stock, net of <span id="xdx_90C_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znJjJmc19LRh" title="Common stock withheld for payroll tax withholdings, shares">14,702</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_901_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220201__20220228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNnHGmdXc1T6" title="Common stock withheld for payroll tax withholdings, value">116,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--VestingAxis__custom--MayTwoThousandNineteenMember_z4GFB9gM9wQ1" title="Number of restricted stock units granted">50,000</span> RSUs granted in May 2019 vested, and in May 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6KSnnTttRRf" title="Number of common stock issued">36,851</span> shares of common stock, net of <span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShares_pid_c20220501__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz6xPk0LF2" title="Common stock withheld for payroll tax withholdings, shares">13,149</span> shares of common stock withheld for payroll tax withholdings totaling $<span id="xdx_903_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20220501__20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEj1Ujusv0D2" title="Common stock withheld for payroll tax withholdings, value">99,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhc508W9ngL7" title="Number of shares isssued">35,693</span> shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the applicable director resigns.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option Plan </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan; however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of September 30, 2022, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zDPUtblVwLc1" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">6,000,000</span> shares of the Company’s common stock. The purposes of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_z84yGZJCV5x6" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">2,058,280</span> shares available for future issuances under the 2017 Plan at September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2hAwRftDnWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option activity under the Plans for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_ztwUvl2oeg4" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of<br/> Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Remaining<br/> Contractual Life</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">Options outstanding – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zrEO9Kmsetk8" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"><span style="font-size: 10pt">3,039,546</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z45eXB2D88Ll" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-size: 10pt">5.52</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Options granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZVH9R5zGWud" style="text-align: right" title="Number of shares, options granted"><span style="font-size: 10pt">323,250</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfesQryhghX4" style="text-align: right" title="Weighted average exercise price, options granted"><span style="font-size: 10pt">7.30</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Options exercised</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWZceTGBOn8l" style="text-align: right" title="Number of shares, options exercised"><span style="font-size: 10pt">(144,270</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlUo5O2WCMw1" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="font-size: 10pt">2.92</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Options cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zni07cCw900l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"><span style="font-size: 10pt">(47,500</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zxXmN3IOmpF7" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited"><span style="font-size: 10pt">7.41</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Options outstanding – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zK6KQKyoeYL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance"><span style="font-size: 10pt">3,171,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zyWp5ozWvEhk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance"><span style="font-size: 10pt">5.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRjBVLYbfQMl" title="Weighted average. remaining contractual life, options outstanding">4.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQlaSa9Twwua" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding"><span style="font-size: 10pt">19,919,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Options exercisable</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgV1ti8nCgQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable"><span style="font-size: 10pt">2,462,904</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zyc5SP4P6jBa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable"><span style="font-size: 10pt">5.33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zw2UgRXc6Pa8" title="Weighted average. remaining contractual life, options exercisable">4.19</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zBBKE3R30kyb" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable"><span style="font-size: 10pt">16,609,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Options vested and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIwQSnA8tY9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest"><span style="font-size: 10pt">3,037,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjjMJQkAeEDl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest"><span style="font-size: 10pt">5.72</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpAly20gf7zc" title="Weighted average. remaining contractual life, options vested and expected to vest">4.57</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVuAvFjg3Kl8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options vested and expected to vest"><span style="font-size: 10pt">19,314,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AC_zaPvm4OaFIY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all shares underlying options with an exercise price lower than the market price on September 30, 2022, based on the closing price of the Company’s common stock of $<span id="xdx_908_ecustom--ClosingPriceOfCommonStockPricePerShare_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_znwhDiGB5Gq7" title="Closing price of common stock price per share">12.07</span> on that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September 30, 2022, the Company granted stock options to certain employees. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dc_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zsFIpA4ddiFa" title="Weighted avg. remaining contractual life, options exercisable">ten years</span>. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_znNo5K71z7Hf" title="Vesting term description">Vesting terms for options granted to employees during the three and nine months ended September 30, 2022 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years</span>. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureFactor_pid_dp_uPure_c20220101__20220930__srt--TitleOfIndividualAxis__custom--EmployeesAndDirectorsMember_zJUhCyvoKWD7" title="Forfeiture factor rate">10</span>%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zL0R6o5jQRN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zLK4IXcp8uY6" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left"><span style="font-size: 10pt">Weighted-average fair value of options granted</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z6w1eA0OE276" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-size: 10pt">4.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Expected terms (in years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLSoFVbALHm4" title="Expected terms (in years)">6.11</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zK8RxzUFgc85" title="Expected volatility">68</span>-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zZvV8Oes1Dz7" title="Expected volatility">70</span></span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Risk-free interest rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zAnDrtDf99dl" title="Risk-free interest rate">1.54</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zYmQFGPdraI4" title="Risk-free interest rate">3.19</span></span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zgRvDNgGRI0e" style="text-align: right" title="Dividend yield"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1563">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zz1XQjFa3239" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zduzwD5rwG99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about stock options outstanding and exercisable at September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 10pt"> <span id="xdx_8B9_z7NDT31N7M0b" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Options Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Options Exercisable</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Range of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Exercise Prices</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life in Years</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: center"><span style="font-size: 10pt">$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrSF1DTOVWG9" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCHsqlGjxvR9" title="Range of Exercise Prices, maximum">2.23</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zvmtyhmpgX2j" style="width: 12%; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">595,612</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zveUfNqV2DY" title="Weighted Average Remaining Contractual Life in Years">4.74</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z22jOxone0r2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.97</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXahbV5F634" style="width: 12%; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">595,612</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSVWW3uJarEe" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.97</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9bZeSMccqfb" title="Range of Exercise Prices, minimum">2.40</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZsRihOBfiUb" title="Range of Exercise Prices, maximum">3.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zWxTQbMXOjDb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">53,568</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zqVU1MddIEKh" title="Weighted Average Remaining Contractual Life in Years">5.80</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfRuOg2rIeD7" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.00</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkFjT3x8TC9" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">44,162</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpeAvXK5iiW" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.90</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSliNHredor1" title="Range of Exercise Prices">3.95</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zKUzuBC8WkD8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">370,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoo06oUFw345" title="Weighted Average Remaining Contractual Life in Years">3.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkSd1LwEHoac" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.95</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zULYd2EFw9va" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">370,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoxfLC6ezXb" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">3.95</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zq1pqdbE6yAa" title="Range of Exercise Prices, minimum">4.08</span> - $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zZT5iLtgonni" title="Range of Exercise Prices, maximum">6.30</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zcc2cyYB1nTb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">578,850</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoklsQzSeag1" title="Weighted Average Remaining Contractual Life in Years">4.61</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zaVA9QhKZmbb" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.76</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zkdWTwdxKuLf" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">540,006</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z25lCxzDd6z5" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.82</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zigQPKT1Ope4" title="Range of Exercise Prices, minimum">6.75</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zOSzE6MgZQy3" title="Range of Exercise Prices, maximum">7.30</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zgqwPo0yLUmh" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">413,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zsxbbFea7zCd" title="Weighted Average Remaining Contractual Life in Years">7.91</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkfSjKv3pCe4" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.18</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z7VF3mfNA6ng" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">237,250</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2Qpvz6e5xp9" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.29</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zKeTQZMbntwk" title="Range of Exercise Prices, minimum">7.37</span> - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBYfVT4O2Xu1" title="Range of Exercise Prices, maximum">7.79</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzAUvkiq3w69" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">287,323</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zbKrWeOycqt5" title="Weighted Average Remaining Contractual Life in Years">5.97</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zIkqI96riell" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.54</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6VK9AuMKsGe" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">140,073</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zabvNiy1Xe06" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.47</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_ziFbAiUzFQNb" title="Range of Exercise Prices">7.87</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUdJtS6z85Yl" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">600,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zi7RekrhFQVb" title="Weighted Average Remaining Contractual Life in Years">2.83</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmfxkP4n7PG" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.87</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z1g8o98qyMcc" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">300,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWl54YavKhYl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.87</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zbZCM8vSE3Dl" title="Range of Exercise Prices, minimum">7.89</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z2cYDm4nFHPl" title="Range of Exercise Prices, maximum">8.75</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4BhZMb2I4m5" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">82,673</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziV9QvN3Dtpf" title="Weighted Average Remaining Contractual Life in Years">3.06</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znTcgK8POUy1" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.06</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zBzPIhTQPs36" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">52,051</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zYDaIJAbHmJ" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.15</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zkXrp8z16f27" title="Range of Exercise Prices">8.98</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zHVVa7PTk0o7" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">10,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zClRNWcg5bZ5" title="Weighted Average Remaining Contractual Life in Years">8.34</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYjDGGaO6ste" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zjodaMIhU2d7" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">3,750</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zl5b15gvXoQl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zc6nOVoFs3A7" title="Range of Exercise Prices">8.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zVli2R5q0vXg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">180,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zz8SaOlF1lqj" title="Weighted Average Remaining Contractual Life in Years">0.59</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_ztRB3ACy93E7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.99</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxjdwibsdK9b" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">180,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z9WDInRJTXHb" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.99</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930_zDEyVESTHy9g" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930_zGhuj2t6OpM4" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930_znxiTAyaU8G1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">3,171,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zUmSEgUwRIF8" title="Weighted Average Remaining Contractual Life in Years">4.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930_zbfeiXHLYGP8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930_zcGCbAqjHqs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">2,462,904</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930_zPkRxIa0SxPi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AB_zIKB5KEnzvvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, there was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zEEfkRc7QQc8" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,830,000</span> of total unrecognized compensation expense related to unvested stock options granted under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_z4gmlZlvfM27" title="Expense expected to recognize over the weighted-average remaining vesting period">4.34</span> years. The stock-based compensation for all stock options was $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zPn5YNU0qoV9" title="Stock-based compensation">241,000</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zI4ZcU3OVLt9" title="Stock-based compensation">771,000</span> during the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20210701__20210930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zlA6A7XSQ4T" title="Stock-based compensation">355,000</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zgVdkqcYU1z1" title="Stock-based compensation">1,376,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value of options exercised during the nine months ended September 30, 2022 was $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zdsGov5sM9h2" title="Intrinsic value of options exercised">794,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units/Performance Stock Units </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zk63llKmte2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s RSU activity (including performance stock units) and related information for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zJuy3mRyc6e8" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted<br/> Average Grant<br/> Date Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-size: 10pt">RSUs unvested – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE8vyEnoeask" style="width: 16%; text-align: right" title="Number of RSUs unvested, outstanding, beginning balance"><span style="font-size: 10pt">2,233,202</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUK0RGiuTmH9" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance"><span style="font-size: 10pt">6.78</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">RSUs granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMziKK5rIeP6" style="text-align: right" title="Number of RSUs granted"><span style="font-size: 10pt">65,615</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvZ2CvXW3yB1" style="text-align: right" title="Weighted average grant date fair value, RSUs granted"><span style="font-size: 10pt">7.62</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">RSUs vested</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOqqpuM6NAcf" style="text-align: right" title="Number of RSUs vested"><span style="font-size: 10pt">(220,693</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znofcx3LwaN1" style="text-align: right" title="Weighted average grant date fair value, RSUs vested"><span style="font-size: 10pt">6.60</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd1JPEVPI7g" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8OhufCfNea4" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">RSUs unvested – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKdKQGvA71v" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, outstanding, ending balance"><span style="font-size: 10pt">2,078,124</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9DTrciimM5h" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance"><span style="font-size: 10pt">6.82</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A4_zh1M5UsAcso5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zaYLdV3XOz08" title="Unrecognized compensation expense related to unvested stock options granted under the plan">5,755,000</span>, which is expected to be recognized over a weighted-average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zgCSSbeKtwNf" title="Expense expected to recognize over the weighted-average remaining vesting period">0.85</span> years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and nine months ended September 30, 2022 was $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zVOBOa0uic3l" title="Stock-based compensation">1,691,000</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_z50BjconVOg4" title="Stock-based compensation">5,170,000</span>, respectively, and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20210701__20210930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zs2AaKDcd1P7" title="Stock-based compensation">1,340,000</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_z1XJqib2aDdi" title="Stock-based compensation">2,167,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company has issued warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHdogHWK8erc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zAzKPiLo2opf" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of Shares<br/> Subject to Warrants<br/> Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-size: 10pt">Warrants outstanding – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zc3SbpbWJsji" style="width: 16%; text-align: right" title="Number of Shares Subject to Warrants Outstanding, Beginning Balance"><span style="font-size: 10pt">373,847</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLurTbeLSFT9" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, Beginning Balance"><span style="font-size: 10pt">2.08</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zm8LN3pp8cp3" style="text-align: right" title="Number of Shares Subject to Warrants Outstanding, Granted"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Exercised</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLtPssm2Y7H9" style="text-align: right" title="Number of Shares Subject to Warrants Outstanding, Exercised"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0WnIoQSWT8l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Subject to Warrants Outstandings, Expirations"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1771">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Warrants outstanding and exercisable – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5H6frYiIixk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Subject to Warrants Outstanding, Ending Balance"><span style="font-size: 10pt">373,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zIW8D9oYzXFd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average. Exercise Price, Ending Balance"><span style="font-size: 10pt">2.08</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Weighted average remaining contractual life of the outstanding warrants in years – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSHnMfnUdJUb" title="Weighted average remaining contractual life of the outstanding warrants in years">1.8</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_8AA_zaQX3EiNyig9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_zHngjfcq7pD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding and exercisable as of September 30, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zf3fk2VAKWPc" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt">Warrant Series</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Issue Date</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Lender warrants</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 14%; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_ztQh2gxtxRQf" title="Issue Date">7/19/2017</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zwAM8wbiNRm3" style="width: 14%; text-align: right" title="Warrants Outstanding"><span style="font-size: 10pt">373,847</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zbkvfMH1Gvle" style="width: 14%; text-align: right" title="Exercise Price"><span style="font-size: 10pt">2.08</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 14%; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zbBIXoPH5QF1" title="Expiration Date">7/19/2024</span></span></td></tr> </table> <p id="xdx_8A3_zjWVc0QbtTib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary Stock-Based Transactions </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220701__20220930__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zDYBJqvibiU5" title="Stock-based compensation"><span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20220101__20220930__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zOAWSf7euL9f" title="Stock-based compensation">0</span></span> in stock-based compensation expense related to subsidiary stock options during the three and nine months ended September 30, 2022, and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20210701__20210930__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_z5rN4LfBsM6" title="Stock-based compensation">2,000</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210101__20210930__us-gaap--AwardTypeAxis__custom--SubsidiaryStockMember_zrvEonoLlAF2" title="Stock-based compensation">87,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation Summary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zBMsRcqkgY43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zDcdO6DqEZxf" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220701__20220930_zTmfVykIZYRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20210701__20210930_zwP2dvruhBmb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20220101__20220930_zzQs07TW3Du4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20210101__20210930_zSCghaJSlfu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Three Months Ended <br/> September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Nine Months Ended <br/> September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zmVeoiuX52B5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left"><span style="font-size: 10pt">Employees – selling, general and administrative</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">1,611,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">1,435,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">4,942,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">2,984,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziOMJpSR3Usg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Employees – R&amp;D</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">163,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">144,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">525,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">328,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zq1SmauMtVZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Directors – selling, general and administrative</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">118,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">337,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">318,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zSrdH1EllUk1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Consultants – R&amp;D</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">33,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">137,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zKDZ2hVOdQU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,932,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,697,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">5,941,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,630,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zonpGZZaaCwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 5000000 5000000 0.001 0.001 0 0 0 0 53594 125000 2.40 36014 35392 295000 4054 15995 7.07 11941 3275 7000 3275 1.70 3.95 50000 29395 20605 162000 50000 24077 25923 204000 35000 20298 14702 116000 50000 36851 13149 99000 35693 6000000 2058280 <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z2hAwRftDnWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of stock option activity under the Plans for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_ztwUvl2oeg4" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of<br/> Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Remaining<br/> Contractual Life</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Aggregate<br/> Intrinsic Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%"><span style="font-size: 10pt">Options outstanding – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zrEO9Kmsetk8" style="width: 12%; text-align: right" title="Number of shares, outstanding, beginning balance"><span style="font-size: 10pt">3,039,546</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z45eXB2D88Ll" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance"><span style="font-size: 10pt">5.52</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"> </span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Options granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZVH9R5zGWud" style="text-align: right" title="Number of shares, options granted"><span style="font-size: 10pt">323,250</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfesQryhghX4" style="text-align: right" title="Weighted average exercise price, options granted"><span style="font-size: 10pt">7.30</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Options exercised</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWZceTGBOn8l" style="text-align: right" title="Number of shares, options exercised"><span style="font-size: 10pt">(144,270</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zlUo5O2WCMw1" style="text-align: right" title="Weighted average exercise price, options exercised"><span style="font-size: 10pt">2.92</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Options cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zni07cCw900l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, options cancelled/forfeited"><span style="font-size: 10pt">(47,500</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zxXmN3IOmpF7" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, options cancelled/forfeited"><span style="font-size: 10pt">7.41</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Options outstanding – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zK6KQKyoeYL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, outstanding, ending balance"><span style="font-size: 10pt">3,171,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zyWp5ozWvEhk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, outstanding, ending balance"><span style="font-size: 10pt">5.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRjBVLYbfQMl" title="Weighted average. remaining contractual life, options outstanding">4.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQlaSa9Twwua" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options outstanding"><span style="font-size: 10pt">19,919,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Options exercisable</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgV1ti8nCgQ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable"><span style="font-size: 10pt">2,462,904</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zyc5SP4P6jBa" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options exercisable"><span style="font-size: 10pt">5.33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zw2UgRXc6Pa8" title="Weighted average. remaining contractual life, options exercisable">4.19</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zBBKE3R30kyb" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options exercisable"><span style="font-size: 10pt">16,609,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Options vested and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zIwQSnA8tY9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options vested and expected to vest"><span style="font-size: 10pt">3,037,832</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjjMJQkAeEDl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price, options vested and expected to vest"><span style="font-size: 10pt">5.72</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpAly20gf7zc" title="Weighted average. remaining contractual life, options vested and expected to vest">4.57</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVuAvFjg3Kl8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate intrinsic value, options vested and expected to vest"><span style="font-size: 10pt">19,314,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 3039546 5.52 323250 7.30 144270 2.92 47500 7.41 3171026 5.79 P4Y7M2D 19919000 2462904 5.33 P4Y2M8D 16609000 3037832 5.72 P4Y6M25D 19314000 12.07 P10Y Vesting terms for options granted to employees during the three and nine months ended September 30, 2022 included the following vesting schedule: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years 0.10 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zL0R6o5jQRN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zLK4IXcp8uY6" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left"><span style="font-size: 10pt">Weighted-average fair value of options granted</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z6w1eA0OE276" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-size: 10pt">4.49</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Expected terms (in years)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLSoFVbALHm4" title="Expected terms (in years)">6.11</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Expected volatility</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zK8RxzUFgc85" title="Expected volatility">68</span>-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zZvV8Oes1Dz7" title="Expected volatility">70</span></span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Risk-free interest rate</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zAnDrtDf99dl" title="Risk-free interest rate">1.54</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zYmQFGPdraI4" title="Risk-free interest rate">3.19</span></span></td><td style="text-align: left"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20220101__20220930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zgRvDNgGRI0e" style="text-align: right" title="Dividend yield"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1563">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 4.49 P6Y1M9D 0.68 0.70 0.0154 0.0319 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zduzwD5rwG99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about stock options outstanding and exercisable at September 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 10pt"> <span id="xdx_8B9_z7NDT31N7M0b" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Options Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Options Exercisable</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Range of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Exercise Prices</span></p></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life in Years</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 18%; text-align: center"><span style="font-size: 10pt">$<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zrSF1DTOVWG9" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zCHsqlGjxvR9" title="Range of Exercise Prices, maximum">2.23</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zvmtyhmpgX2j" style="width: 12%; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">595,612</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zveUfNqV2DY" title="Weighted Average Remaining Contractual Life in Years">4.74</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z22jOxone0r2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">1.97</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zXahbV5F634" style="width: 12%; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">595,612</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zSVWW3uJarEe" style="width: 12%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">1.97</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9bZeSMccqfb" title="Range of Exercise Prices, minimum">2.40</span> - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zZsRihOBfiUb" title="Range of Exercise Prices, maximum">3.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zWxTQbMXOjDb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">53,568</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zqVU1MddIEKh" title="Weighted Average Remaining Contractual Life in Years">5.80</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfRuOg2rIeD7" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.00</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zkFjT3x8TC9" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">44,162</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zpeAvXK5iiW" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">2.90</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zSliNHredor1" title="Range of Exercise Prices">3.95</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zKUzuBC8WkD8" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">370,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoo06oUFw345" title="Weighted Average Remaining Contractual Life in Years">3.50</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zkSd1LwEHoac" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">3.95</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zULYd2EFw9va" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">370,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zoxfLC6ezXb" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">3.95</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zq1pqdbE6yAa" title="Range of Exercise Prices, minimum">4.08</span> - $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zZT5iLtgonni" title="Range of Exercise Prices, maximum">6.30</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zcc2cyYB1nTb" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">578,850</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zoklsQzSeag1" title="Weighted Average Remaining Contractual Life in Years">4.61</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zaVA9QhKZmbb" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.76</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zkdWTwdxKuLf" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">540,006</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_z25lCxzDd6z5" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.82</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zigQPKT1Ope4" title="Range of Exercise Prices, minimum">6.75</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zOSzE6MgZQy3" title="Range of Exercise Prices, maximum">7.30</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zgqwPo0yLUmh" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">413,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zsxbbFea7zCd" title="Weighted Average Remaining Contractual Life in Years">7.91</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_zkfSjKv3pCe4" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.18</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z7VF3mfNA6ng" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">237,250</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFiveMember_z2Qpvz6e5xp9" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.29</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zKeTQZMbntwk" title="Range of Exercise Prices, minimum">7.37</span> - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zBYfVT4O2Xu1" title="Range of Exercise Prices, maximum">7.79</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zzAUvkiq3w69" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">287,323</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zbKrWeOycqt5" title="Weighted Average Remaining Contractual Life in Years">5.97</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zIkqI96riell" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.54</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_z6VK9AuMKsGe" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">140,073</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSixMember_zabvNiy1Xe06" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.47</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_ziFbAiUzFQNb" title="Range of Exercise Prices">7.87</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zUdJtS6z85Yl" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">600,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zi7RekrhFQVb" title="Weighted Average Remaining Contractual Life in Years">2.83</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zmfxkP4n7PG" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">7.87</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_z1g8o98qyMcc" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">300,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeSevenMember_zWl54YavKhYl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">7.87</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zbZCM8vSE3Dl" title="Range of Exercise Prices, minimum">7.89</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z2cYDm4nFHPl" title="Range of Exercise Prices, maximum">8.75</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_z4BhZMb2I4m5" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">82,673</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_ziV9QvN3Dtpf" title="Weighted Average Remaining Contractual Life in Years">3.06</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_znTcgK8POUy1" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.06</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zBzPIhTQPs36" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">52,051</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeEightMember_zYDaIJAbHmJ" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.15</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: center"><span style="font-size: 10pt">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zkXrp8z16f27" title="Range of Exercise Prices">8.98</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zHVVa7PTk0o7" style="text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">10,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zClRNWcg5bZ5" title="Weighted Average Remaining Contractual Life in Years">8.34</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zYjDGGaO6ste" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zjodaMIhU2d7" style="text-align: right" title="Number Exercisable"><span style="font-size: 10pt">3,750</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeNineMember_zl5b15gvXoQl" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.98</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zc6nOVoFs3A7" title="Range of Exercise Prices">8.99</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zVli2R5q0vXg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">180,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zz8SaOlF1lqj" title="Weighted Average Remaining Contractual Life in Years">0.59</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_ztRB3ACy93E7" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">8.99</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_zxjdwibsdK9b" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">180,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTenMember_z9WDInRJTXHb" style="padding-bottom: 1pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">8.99</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: center"><span style="font-size: 10pt">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20220101__20220930_zDEyVESTHy9g" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20220101__20220930_zGhuj2t6OpM4" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220930_znxiTAyaU8G1" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-size: 10pt">3,171,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930_zUmSEgUwRIF8" title="Weighted Average Remaining Contractual Life in Years">4.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220930_zbfeiXHLYGP8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-size: 10pt">5.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220930_zcGCbAqjHqs2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"><span style="font-size: 10pt">2,462,904</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220930_zPkRxIa0SxPi" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-size: 10pt">5.33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 1.47 2.23 595612 P4Y8M26D 1.97 595612 1.97 2.40 3.50 53568 P5Y9M18D 3.00 44162 2.90 3.95 370000 P3Y6M 3.95 370000 3.95 4.08 6.30 578850 P4Y7M9D 5.76 540006 5.82 6.75 7.30 413000 P7Y10M28D 7.18 237250 7.29 7.37 7.79 287323 P5Y11M19D 7.54 140073 7.47 7.87 600000 P2Y9M29D 7.87 300000 7.87 7.89 8.75 82673 P3Y21D 8.06 52051 8.15 8.98 10000 P8Y4M2D 8.98 3750 8.98 8.99 180000 P0Y7M2D 8.99 180000 8.99 1.47 8.99 3171026 P4Y7M2D 5.79 2462904 5.33 1830000 P4Y4M2D 241000 771000 355000 1376000 794000 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zk63llKmte2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s RSU activity (including performance stock units) and related information for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zJuy3mRyc6e8" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of RSUs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted<br/> Average Grant<br/> Date Fair Value</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-size: 10pt">RSUs unvested – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE8vyEnoeask" style="width: 16%; text-align: right" title="Number of RSUs unvested, outstanding, beginning balance"><span style="font-size: 10pt">2,233,202</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUK0RGiuTmH9" style="width: 16%; text-align: right" title="Weighted average grant date fair value, beginning balance"><span style="font-size: 10pt">6.78</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">RSUs granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMziKK5rIeP6" style="text-align: right" title="Number of RSUs granted"><span style="font-size: 10pt">65,615</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvZ2CvXW3yB1" style="text-align: right" title="Weighted average grant date fair value, RSUs granted"><span style="font-size: 10pt">7.62</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">RSUs vested</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOqqpuM6NAcf" style="text-align: right" title="Number of RSUs vested"><span style="font-size: 10pt">(220,693</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znofcx3LwaN1" style="text-align: right" title="Weighted average grant date fair value, RSUs vested"><span style="font-size: 10pt">6.60</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxd1JPEVPI7g" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8OhufCfNea4" style="padding-bottom: 1pt; text-align: right" title="Weighted average grant date fair value, RSUs cancelled/forfeited"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">RSUs unvested – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKdKQGvA71v" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, outstanding, ending balance"><span style="font-size: 10pt">2,078,124</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9DTrciimM5h" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average grant date fair value, ending balance"><span style="font-size: 10pt">6.82</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 2233202 6.78 65615 7.62 220693 6.60 2078124 6.82 5755000 P0Y10M6D 1691000 5170000 1340000 2167000 <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zHdogHWK8erc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity for the nine months ended September 30, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zAzKPiLo2opf" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of Shares<br/> Subject to Warrants<br/> Outstanding</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Weighted Average<br/> Exercise Price</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-size: 10pt">Warrants outstanding – January 1, 2022</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zc3SbpbWJsji" style="width: 16%; text-align: right" title="Number of Shares Subject to Warrants Outstanding, Beginning Balance"><span style="font-size: 10pt">373,847</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLurTbeLSFT9" style="width: 16%; text-align: right" title="Weighted Average. Exercise Price, Outstanding, Beginning Balance"><span style="font-size: 10pt">2.08</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Granted</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zm8LN3pp8cp3" style="text-align: right" title="Number of Shares Subject to Warrants Outstanding, Granted"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1767">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Exercised</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zLtPssm2Y7H9" style="text-align: right" title="Number of Shares Subject to Warrants Outstanding, Exercised"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1769">-</span></span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0WnIoQSWT8l" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Subject to Warrants Outstandings, Expirations"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1771">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Warrants outstanding and exercisable – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5H6frYiIixk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Subject to Warrants Outstanding, Ending Balance"><span style="font-size: 10pt">373,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_pid_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zIW8D9oYzXFd" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average. Exercise Price, Ending Balance"><span style="font-size: 10pt">2.08</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Weighted average remaining contractual life of the outstanding warrants in years – September 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSHnMfnUdJUb" title="Weighted average remaining contractual life of the outstanding warrants in years">1.8</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 373847 2.08 373847 2.08 P1Y9M18D <p id="xdx_89F_ecustom--ScheduleofWarrantsOutstandingTableTextBlock_zHngjfcq7pD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding and exercisable as of September 30, 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zf3fk2VAKWPc" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt">Warrant Series</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Issue Date</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Lender warrants</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 14%; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_ecustom--WarrantsIssuanceDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_ztQh2gxtxRQf" title="Issue Date">7/19/2017</span></span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zwAM8wbiNRm3" style="width: 14%; text-align: right" title="Warrants Outstanding"><span style="font-size: 10pt">373,847</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zbkvfMH1Gvle" style="width: 14%; text-align: right" title="Exercise Price"><span style="font-size: 10pt">2.08</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 14%; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zbBIXoPH5QF1" title="Expiration Date">7/19/2024</span></span></td></tr> </table> 2017-07-19 373847 2.08 2024-07-19 0 0 2000 87000 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zBMsRcqkgY43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zDcdO6DqEZxf" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220701__20220930_zTmfVykIZYRa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20210701__20210930_zwP2dvruhBmb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20220101__20220930_zzQs07TW3Du4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49D_20210101__20210930_zSCghaJSlfu8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Three Months Ended <br/> September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For the Nine Months Ended <br/> September 30,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zmVeoiuX52B5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left"><span style="font-size: 10pt">Employees – selling, general and administrative</span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">1,611,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">1,435,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">4,942,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td><td style="width: 2%"><span style="font-size: 10pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">2,984,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_ziOMJpSR3Usg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Employees – R&amp;D</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">163,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">144,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">525,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">328,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zq1SmauMtVZc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Directors – selling, general and administrative</span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">125,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">118,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">337,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td><td><span style="font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-size: 10pt">318,000</span></td><td style="text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_hsrt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zSrdH1EllUk1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Consultants – R&amp;D</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">33,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1815">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">137,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_zKDZ2hVOdQU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,932,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">1,697,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">5,941,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">3,630,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt"> </span></td></tr> </table> 1611000 1435000 4942000 2984000 163000 144000 525000 328000 125000 118000 337000 318000 33000 137000 1932000 1697000 5941000 3630000 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zKMZKi5MuKa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15. <span id="xdx_828_zvzTiltydGw6">COMMITMENTS AND CONTINGENCIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General and Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product and Professional Liability</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Klarity License Agreement – Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a license agreement in April 2017, as amended in April 2018 (the “Klarity License Agreement”), with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z2WtRNy9kBGj" title="Royalty payment description">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold</span>. In addition, the Company was required to make certain milestone payments to Dr. Lindstrom. All of the above referenced milestone payments were payable at the Company’s election in cash or shares of the Company’s restricted common stock. Payments totaling $<span id="xdx_904_ecustom--MilestonePaymentInCash_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zqmhvW0X7jY7" title="Milestone payment in cash">77,000</span> and $<span id="xdx_90E_ecustom--MilestonePaymentInCash_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zb1BQKcvFPck" title="Milestone payment in cash">199,000</span> were made during the three and nine months ended September 30, 2022, respectively, compared to $<span id="xdx_905_ecustom--MilestonePaymentInCash_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zu10H7iejAqc" title="Milestone payment in cash">44,000</span> and $<span id="xdx_900_ecustom--MilestonePaymentInCash_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_znuyI0v3NRw2" title="Milestone payment in cash">114,000</span> during the same periods in 2021, respectively. Royalty expenses were $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zznRDY7mkvq1" title="Royalty expenses">67,000</span> and $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z9tOnCfPVuql" title="Royalty expenses">244,000</span> during the three and nine months ended September 30, 2022, respectively, compared to $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zR4UFiijaI7k" title="Royalty expenses">51,000</span> and $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zVtpUVoAMIye" title="Royalty expenses">130,000</span> during the same periods in 2021, respectively, and were included in accounts payable to Dr. Lindstrom.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Injectable Asset Purchase Agreement – Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zTkuWp1sILG9" title="Royalty payment description">Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold</span>. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_90F_ecustom--InitialMilestonePayment_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zRVCamv7GLQ8" title="Initial milestone payment">33,000</span> upon execution of the Lindstrom APA. Dr. Lindstrom was paid $<span id="xdx_90D_ecustom--MilestonePaymentInCash_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zHTHnIj2Lz1e" title="Milestone payment in cash">8,000</span> and $<span id="xdx_901_ecustom--MilestonePaymentInCash_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zNO9MoXZNjQj" title="Milestone payment in cash">23,000</span> in cash during the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_902_ecustom--MilestonePaymentInCash_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zEbp1IK2nang" title="Milestone payment in cash">7,000</span> and $<span id="xdx_900_ecustom--MilestonePaymentInCash_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_z1NI3AcyLcc1" title="Milestone payment in cash">21,000</span> during the same periods in 2021, respectively. The Company incurred $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zTHrqK0zPZMh" title="Royalty expenses">9,000</span> and $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_z348VeITih9k" title="Royalty expenses">24,000</span> for royalty expenses related to the Lindstrom APA during the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_znb41u3NGY7g" title="Royalty expenses">7,000</span> and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zgwpXOgwev55" title="Royalty expenses">21,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Presbyopia Asset Purchase Agreement – Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company entered into an asset purchase agreement (the “Presbyopia APA”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product to treat presbyopia (the “Presbyopia Product”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of the Presbyopia APA, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__us-gaap--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zR4PN2NHiII5" title="Royalty payment description">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold</span>. Dr. Lindstrom was paid $<span id="xdx_908_ecustom--MilestonePaymentInCash_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zUkEw4Qx3Tme" title="Milestone payment in cash"><span id="xdx_90E_ecustom--MilestonePaymentInCash_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zlq8oITWwDKi" title="Milestone payment in cash"><span id="xdx_90A_ecustom--MilestonePaymentInCash_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_z2HkVQaRvWsh" title="Milestone payment in cash"><span id="xdx_90E_ecustom--MilestonePaymentInCash_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zIilyFAGOB19" title="Milestone payment in cash">0</span></span></span></span> in cash during the three and nine month periods ended September 30, 2022 and 2021, and was due $<span id="xdx_906_ecustom--MilestonePaymentsOnPayables_iI_c20220930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zcsFKn4C9lY" title="Milestone payment in cash"><span id="xdx_90B_ecustom--MilestonePaymentsOnPayables_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_z0oNSY4m4B4k" title="Milestone payment in cash">0</span></span> at September 30, 2022 and 2021. The Company incurred $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zsTl9QHGvcul" title="Royalty expense"><span id="xdx_903_eus-gaap--RoyaltyExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_z66qxmYXf3F8" title="Royalty expense"><span id="xdx_90E_eus-gaap--RoyaltyExpense_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_z2sZMBZooQzi" title="Royalty expense"><span id="xdx_90E_eus-gaap--RoyaltyExpense_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember_zacsuh4juEm6" title="Royalty expense">0</span></span></span></span> for royalty expenses related to the Presbyopia APA during the three and nine month periods ended September 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset Purchase, License and Related Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. During the three and nine months ended September 30, 2022, $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_znKaTH1RmCuk" title="Royalty expense">185,000</span> and $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zJRaPa3HgW07" title="Royalty expense">695,000</span> were incurred under these agreements as royalty expenses, respectively, and $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zxlhPMw6dkA9" title="Royalty expense">285,000</span> and $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseLicenseAndRelatedAgreementsMember_zkJk0kAgmQn7" title="Royalty expense">778,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sintetica Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, the Company entered into a License and Supply Agreement (the “Sintetica Agreement”) with Sintetica S.A. (“Sintetica”), pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate (“IHEEZO”) in the U.S. and Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Sintetica Agreement, the Company agreed to pay Sintetica a per unit transfer price to supply IHEEZO, along with a per unit royalty for units sold. The Company is required to pay Sintetica up to $<span id="xdx_906_eus-gaap--PaymentsForRoyalties_c20210701__20210731__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zOrDqMW5DVa3" title="Royalty payments">18,000,000</span> in one-time milestone payments including a $<span id="xdx_900_eus-gaap--PaymentsForRoyalties_c20210701__20210731__srt--StatementScenarioAxis__custom--DueWithinThirtyDaysMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_zFi85SQ9RRvd" title="Royalty payments">5,000,000</span> payment (the “Upfront Payment”) due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica is responsible for regulatory filings for IHEEZO in the U.S. The Upfront Payment along with an additional milestone payment of $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zmtw30TJQqR4" title="Royalty payments">3,117,000</span> was paid and recorded as R&amp;D expenses during the year ended December 31, 2021. During the three and nine months ended September 30, 2022, $<span id="xdx_906_ecustom--PurchaseOfIntangibleAssetIncludedInAccountsPayableAndAccruedExpenses_c20220701__20220930_zf2YLhK13Kng"><span id="xdx_90E_ecustom--PurchaseOfIntangibleAssetIncludedInAccountsPayableAndAccruedExpenses_c20220101__20220930_zCfwdN2vXKO1">5,000,000</span></span> was accrued under the Sintetica Agreement related to the FDA approval of the United States NDA for IHEEZO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain limitations, the Sintetica Agreement has a ten-year term, and allows for a ten-year extension if certain sales thresholds are met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wakamoto Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In August 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement (together, the “Wakamoto Agreements”) with Wakamoto Pharmaceutical Co., Ltd. (“Wakamoto”), pursuant to which Wakamoto granted the Company the exclusive license and marketing rights to its ophthalmic drug candidate (“MAQ-100”) in the U.S. and Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the <span style="background-color: white">Wakamoto </span>Agreements, Wakamoto agreed to supply MAQ-100 to the Company, and the Company agreed to pay Wakamoto a per unit transfer price to supply MAQ-100. In addition, the Company is required to pay Wakamoto various one-time milestone payments totaling up to $<span id="xdx_905_eus-gaap--PaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_z2qLUZSOPYDa" title="Payment for royalties">2,000,000</span> upon the achievement of certain regulatory milestones and up to $<span id="xdx_906_ecustom--CommercialPaymentsForRoyalties_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--WakamotoAgreementMember_zyQ6yN0bHYu" title="Commercial payments for royalties">6,200,000</span> upon the achievement of certain commercial milestones. Under the terms of the Wakamoto Agreements, the Company is responsible for regulatory filings and fees for MAQ-100 in the U.S. and Canada. Through September 30, 2022, no amounts have been paid or accrued under the Wakamoto Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to certain limitations, the term of the Wakamoto Agreements is five years from the date of the FDA’s market approval of MAQ-100 with a five-year extension if certain unit sales thresholds are met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Eyepoint Commercial Alliance Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU^® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the United States.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint pays the Company a fee calculated based on the quarterly sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the <span style="background-color: white">Dexycu Agreement</span>, the Company agreed to use commercially reasonable efforts to promote and market DEXYCU in the U.S.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to a mutual termination agreement entered into on October 7, 2022 the <span style="background-color: white">Dexycu Agreement</span> will terminate on January 1, 2023 (see Note 17 for more information). During the three and nine months ended September 30, 2022, the Company recorded $<span id="xdx_90F_ecustom--CommissionRevenues_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zOfUtx6gamk4" title="Commission revenues">1,044,000</span> and $<span id="xdx_905_ecustom--CommissionRevenues_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_znhx25hljJki" title="Commission revenues">3,576,000</span>, respectively, and $<span id="xdx_90A_ecustom--CommissionRevenues_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zf3fk2t8EeO4" title="Commission revenues">900,000</span> and $<span id="xdx_904_ecustom--CommissionRevenues_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_zt2c9ht8oZV6" title="Commission revenues">2,212,000</span> during the same periods in 2021, respectively, in commission revenues related to the Dexycu Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales and Marketing Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and marketing representation services to Harrow in select geographies in the U.S. in connection with the Company’s ophthalmic pharmaceutical compounded formulations or related products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--DescriptionForCommissionPayments_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zzbhgdez1aJ1" title="Description for commission payments">Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to <span id="xdx_902_ecustom--CommissionPaymentsPercentage_dp_uPure_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_zAY4fzcDt57b" title="Commission payments percentage">10%</span> to <span id="xdx_903_ecustom--CommissionPaymentsPercentage_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zzqvFMWaxQFj" title="Commission payments percentage">14%</span> of net sales for products above and beyond the initial existing sales amounts</span>. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms. Commission expenses of $<span id="xdx_90C_eus-gaap--SalesCommissionsAndFees_c20220701__20220930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_znZ0vTNIEqs" title="Commission expenses">1,041,000</span> and $<span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_c20220101__20220930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zsDDNwSqAXIh" title="Commission expenses">3,188,000</span> were incurred under these agreements for commission expenses during the three and nine months ended September 30, 2022, respectively, and $<span id="xdx_90E_eus-gaap--SalesCommissionsAndFees_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zhgfcW2Deizb" title="Commission expenses">953,000</span> and $<span id="xdx_906_eus-gaap--SalesCommissionsAndFees_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z9EBngFyAVVe" title="Commission expenses">2,766,000</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold 77000 199000 44000 114000 67000 244000 51000 130000 Under the terms of the Lindstrom APA, the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold 33000 8000 23000 7000 21000 9000 24000 7000 21000 the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold 0 0 0 0 0 0 0 0 0 0 185000 695000 285000 778000 18000000 5000000 3117000 5000000 5000000 2000000 6200000 1044000 3576000 900000 2212000 Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts 0.10 0.14 1041000 3188000 953000 2766000 <p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_zxaaKrfQ1IVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16. <span id="xdx_821_zwpAAtxZJAy9">CONCENTRATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two products that each comprised more than 10% of total revenues during the three and nine month periods ended September 30 2022 and 2021, respectively. These products collectively accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zQE6i7KjQHdd" title="Concentration risk percentage">34%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8L7qQSH2Zf5" title="Concentration risk percentage">33%</span> of revenues during the three and nine months ended September 30, 2022, respectively, and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z7fmXtSRtcle" title="Concentration risk percentage">35%</span> and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zUtpVpGraFsj" title="Concentration risk percentage">36%</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales during the three and nine months ended September 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zF08h1SpDj5a" title="Concentration risk percentage">52%</span> and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zmCGMwveX5M4" title="Concentration risk percentage">66%</span> of active pharmaceutical ingredient purchases during the three and nine months ended September 30, 2022, respectively, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zBmvtIsvEi76" title="Concentration risk percentage">59%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zJ0jSzM2Iupf" title="Concentration risk percentage">71%</span> during the same periods in 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.34 0.33 0.35 0.36 0.52 0.66 0.59 0.71 <p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zPLMG1waWwU7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17. <span id="xdx_829_zbLKhMB69r2j">SUBSEQUENT EVENTS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has performed an evaluation of events occurring subsequent to September 30, 2022 through the filing date of this Quarterly Report. Based on its evaluation, no events other than those described below need to be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, t<span style="background-color: white">he Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221001__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zscwph9bd2pl" title="Number of common stock issued">306,347</span> shares of its common stock upon the cashless exercise of warrants to purchase <span id="xdx_905_ecustom--CashlessExerciseOfWarrantsToPurchaseToCommonStock_iI_pid_c20221031__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zD0fXK1xZcai" title="Cashless exercise of warrants to purchase to common stock">373,847</span> shares of common stock, with an exercise price $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221031__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8slg2mI4vzl" title="Warrants exercise price">2.08</span> per share.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221001__20221031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM7NJFvTnKo7" title="Number of common stock issued">31,000</span> shares of common stock upon the exercise of options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pid_c20221001__20221031__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsQUUpnEDB8g" title="Exercise of option, shares">31,000</span> shares of common stock at exercise prices of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221001__20221031__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MinimumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zErvePUIKB55" title="Exercise price">1.70</span> - $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20221001__20221031__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyxoTiOa2n4j" title="Exercise price">8.40</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eyepoint Termination</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Following the preliminary Hospital Outpatient Prospective Payment System (HOPPS) rule proposed by the Centers for Medicare &amp; Medicaid Services (CMS) in July of 2022, which did not contain an extension of the pass-through payment period for Dexycu beyond December 31, 2022, the Company entered into a Mutual Termination Agreement (the “Termination Agreement”) with Eyepoint on October 7, 2022, pursuant to which Eyepoint and the Company agreed (a) that the Company will continue to support the sale of Dexycu through the fourth quarter of 2022, consistent with the Company’s level of effort during the January through June 2022 period, (b) to decrease the required minimum quarterly sales levels based on Dexycu unit demand for the fourth quarter of 2022, and (c) to terminate the Dexycu Agreement, along with ancillary letter agreements, effective January 1, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Divestment of Non-Ophthalmology Revenues</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, wholly-owned subsidiaries of the Company (“Imprimis”) entered into an Asset Purchase Agreement (the “RPC Agreement”) with Innovation Compounding Pharmacy, LLC (the “Buyer”). The closing of the RPC Agreement was made effective on September 30, 2022; however, control of the assets transferred to the Buyer, and a closing payment was made, in October 2022. Under the terms of the RPC Agreement, Imprimis agreed to sell substantially all of its assets associated with its non-ophthalmology related compounding product line, including but not limited to, certain intellectual property rights, customer lists, databases, and formulations (the “RPC Assets”). The Buyer agreed to make offers of employment to six of the Company’s employees that were responsible for the sales activities associated with the RPC Assets. In connection with the RPC Agreement, Imprimis entered into a separate transition services agreement with the Buyer related to providing on going services, such as procuring and dispensing prescription orders associated with RPC Assets. The Company expects Imprimis to provide transition services to the Buyer for up to six months following the effective date of the RPC Agreement. Under the terms of the RPC Agreement, the Buyer paid Imprimis an aggregate cash amount of $<span id="xdx_900_eus-gaap--ProceedsFromCollaborators_pid_c20221001__20221030__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zAd416qsr5Gc" title="Proceeds from related party">6,000,000</span> in October 2022. In addition, the Buyer is obligated to pay up to $<span id="xdx_905_ecustom--MilestonesReceivableBasedOnAgreedRevenues_iI_pp0p0_c20221030__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zt5CmUw0Zwm5" title="Milestones receivable based on agreed revenues">4,500,000</span> to Imprimis based on mutually agreed upon revenue milestones during the calendar year 2023. The Company determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results.</span></p> 306347 373847 2.08 31000 31000 1.70 8.40 6000000 4500000